BCAT2

UniProt ID: O15382
Organism: Homo sapiens
Review Status: INITIALIZED
📝 Provide Detailed Feedback

Gene Description

BCAT2 (BCAT(m)) is the mitochondrial branched-chain-amino-acid aminotransferase, a class-IV pyridoxal 5'-phosphate (PLP)-dependent enzyme (EC 2.6.1.42) that catalyzes the first, reversible step of branched-chain amino acid (BCAA) catabolism. It transaminates L-leucine, L-isoleucine and L-valine with 2-oxoglutarate (alpha-ketoglutarate) to yield the corresponding branched-chain 2-oxo (keto) acids (4-methyl-2-oxopentanoate/KIC, (S)-3-methyl-2-oxopentanoate/KMV and 3-methyl-2-oxobutanoate/KIV) plus L-glutamate. The branched-chain keto acids are then passed to the mitochondrial branched-chain ketoacid dehydrogenase (BCKDH) complex for irreversible oxidative decarboxylation. The enzyme functions as a PLP-bound homodimer in the mitochondrial matrix, with the PLP cofactor forming a Schiff base (internal aldimine) to an active-site lysine (Lys-229), and carries a redox-active CXXC center (Cys-342/Cys-345) near the active site that couples catalysis to thiol redox state. BCAT2 is broadly expressed with highest activity in extrahepatic tissues such as skeletal muscle; the paralog BCAT1 is the cytosolic isozyme. Because BCAAs are essential amino acids in humans, the physiological direction of the reaction is catabolic (nitrogen removal), and loss of BCAT2 function causes an autosomal-recessive inborn error of metabolism (hypervalinemia and hyperleucine-isoleucinemia) with elevated plasma BCAAs.

Existing Annotations Review

GO Term Evidence Action Reason
GO:0005739 mitochondrion
IBA
GO_REF:0000033
ACCEPT
Summary: Phylogenetic (PAN-GO) inference that BCAT2 is active in the mitochondrion. Consistent with the cleaved N-terminal mitochondrial transit peptide (residues 1-27) and with all experimental localization evidence.
Reason: BCAT2 has a 27-residue mitochondrial targeting presequence and is well established as a mitochondrial-matrix enzyme; the IBA is correct. Mitochondrial matrix (GO:0005759) is the more specific location captured elsewhere in the annotation set.
Supporting Evidence:
PMID:9165094
encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
GO:0006550 L-isoleucine catabolic process
IBA
GO_REF:0000033
ACCEPT
Summary: Phylogenetic inference that BCAT2 is involved in L-isoleucine catabolism. BCAT2 transaminates isoleucine as the committed first step of its catabolism.
Reason: Isoleucine transamination is a core BCAT2 activity (GO:0052656), and the enzyme initiates isoleucine catabolism. Direct process annotation is appropriate and core.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0006574 L-valine catabolic process
IBA
GO_REF:0000033
ACCEPT
Summary: Phylogenetic inference that BCAT2 is involved in L-valine catabolism, initiating valine breakdown by transamination to 3-methyl-2-oxobutanoate.
Reason: Valine transamination (GO:0052655) is a core BCAT2 activity; the enzyme initiates valine catabolism. Valine is the most conspicuously elevated BCAA in BCAT2 deficiency, underscoring its physiological role here.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0052654 L-leucine:2-oxoglutarate transaminase activity
IBA
GO_REF:0000033
ACCEPT
Summary: Phylogenetic inference of L-leucine:2-oxoglutarate transaminase activity, one of the three substrate-specific BCAT activities. Corroborated by IDA (PMID:8702755) and Rhea IEA.
Reason: This substrate-specific molecular function is directly demonstrated for BCAT2 and is one of its core enzymatic activities.
Supporting Evidence:
PMID:8702755
code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
GO:0052655 L-valine:2-oxoglutarate transaminase activity
IBA
GO_REF:0000033
ACCEPT
Summary: Phylogenetic inference of L-valine:2-oxoglutarate transaminase activity. Corroborated by IDA (PMID:8702755) and Rhea IEA (RHEA:24813).
Reason: Core substrate-specific transaminase activity of BCAT2, directly measured with valine as substrate.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0052656 L-isoleucine:2-oxoglutarate transaminase activity
IBA
GO_REF:0000033
ACCEPT
Summary: Phylogenetic inference of L-isoleucine:2-oxoglutarate transaminase activity. Corroborated by IDA (PMID:8702755) and Rhea IEA (RHEA:24801).
Reason: Core substrate-specific transaminase activity of BCAT2, directly measured with isoleucine as substrate.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0003824 catalytic activity
IEA
GO_REF:0000002
MARK AS OVER ANNOTATED
Summary: InterPro2GO mapping to the root catalytic-activity term. Correct but uninformative: BCAT2 is a specific PLP-dependent transaminase.
Reason: GO:0003824 is a very general parent of the specific branched-chain aminotransferase activity (GO:0004084) and substrate-specific transaminase terms already annotated. It conveys no information beyond "is an enzyme" and is subsumed by the more precise MF annotations.
GO:0004084 branched-chain-amino-acid:2-oxoglutarate transaminase activity
IEA
GO_REF:0000120
ACCEPT
Summary: Combined multi-method IEA (ARBA + orthology + InterPro + EC:2.6.1.42) assigning the general branched-chain aminotransferase molecular function. This is the correct core EC-level activity.
Reason: GO:0004084 is the primary molecular function of BCAT2 (EC 2.6.1.42) and is independently supported by direct experimental evidence (IDA PMID:8702755) and TAS (PMID:9165094).
Supporting Evidence:
PMID:8702755
code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
GO:0005739 mitochondrion
IEA
GO_REF:0000120
ACCEPT
Summary: IEA localization to mitochondrion (orthology to mouse O35855 plus UniProt SubCell SL-0173). Consistent with all other localization evidence.
Reason: Mitochondrial localization is firmly established; matrix is the specific compartment.
Supporting Evidence:
PMID:9165094
encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
GO:0009081 branched-chain amino acid metabolic process
IEA
GO_REF:0000002
KEEP AS NON CORE
Summary: InterPro2GO mapping to the general BCAA metabolic process. Correct but a broad parent of the specific catabolic-process annotations.
Reason: GO:0009081 (BCAA metabolic process) is a correct but general parent of the more specific and physiologically directional BCAA catabolic process (GO:0009083) and the amino-acid-specific catabolic terms already annotated. Keep as non-core; the catabolic terms carry the core signal.
GO:0009082 branched-chain amino acid biosynthetic process
IEA
GO_REF:0000117
MARK AS OVER ANNOTATED
Summary: ARBA machine-learning IEA (and an older TAS) annotating branched-chain amino acid BIOSYNTHETIC process. The BCAT reaction is chemically reversible, but in humans BCAAs are essential and are not synthesized de novo; the physiological direction is catabolic.
Reason: The reversible transamination can in principle re-aminate branched-chain keto acids, but net de novo BCAA biosynthesis is a bacterial/plant/fungal role of BCAT-family enzymes (e.g. IlvE), not the human physiological function. The biosynthetic-process annotation is transferred from the family/EC and over-states the in vivo role; the catabolic annotations are correct and core. (Retained as an over-annotation rather than removed, since the underlying reversible chemistry is real.)
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0009083 branched-chain amino acid catabolic process
IEA
GO_REF:0000117
ACCEPT
Summary: ARBA IEA to branched-chain amino acid catabolic process. This is the correct core biological process for BCAT2 and is independently supported by direct experimental evidence (IDA on the same term, PMID:8702755).
Reason: BCAT2 catalyzes the committed first step of BCAA catabolism; this is its central physiological role.
Supporting Evidence:
PMID:8702755
code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
file:human/BCAT2/BCAT2-deep-research-falcon.md
BCAT2 catalyzes the first step in mitochondrial BCAA catabolism
GO:0052654 L-leucine:2-oxoglutarate transaminase activity
IEA
GO_REF:0000116
ACCEPT
Summary: Rhea-based IEA (RHEA:18321) for L-leucine:2-oxoglutarate transaminase activity. Matches the UniProt CATALYTIC ACTIVITY reaction for leucine.
Reason: Directly corresponds to a UniProt-documented catalytic reaction of BCAT2 and duplicates the experimentally supported (IDA/IBA) substrate-specific MF; correct and core.
Supporting Evidence:
PMID:8702755
code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
GO:0052655 L-valine:2-oxoglutarate transaminase activity
IEA
GO_REF:0000116
ACCEPT
Summary: Rhea-based IEA (RHEA:24813) for L-valine:2-oxoglutarate transaminase activity, matching the UniProt CATALYTIC ACTIVITY reaction for valine.
Reason: Directly corresponds to a UniProt-documented catalytic reaction of BCAT2; core substrate-specific activity.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0052656 L-isoleucine:2-oxoglutarate transaminase activity
IEA
GO_REF:0000116
ACCEPT
Summary: Rhea-based IEA (RHEA:24801) for L-isoleucine:2-oxoglutarate transaminase activity, matching the UniProt CATALYTIC ACTIVITY reaction for isoleucine.
Reason: Directly corresponds to a UniProt-documented catalytic reaction of BCAT2; core substrate-specific activity.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0005515 protein binding
IPI
PMID:28514442
Architecture of the human interactome defines protein commun...
MARK AS OVER ANNOTATED
Summary: Interaction detected in the BioPlex 2.0 high-throughput AP-MS interactome screen (interactors include HSPD1/P10809 and YBEY/P58557). "Protein binding" is uninformative about BCAT2's molecular function.
Reason: GO:0005515 "protein binding" from a proteome-scale AP-MS screen conveys no specific functional information and is discouraged for core-function purposes. Per curation policy the experimental IPI is retained rather than removed, but it is marked as an over-annotation. (The BCAT2-HSPD1/HSP60 co-purification plausibly reflects mitochondrial chaperone association rather than a discrete functional partnership.)
Supporting Evidence:
PMID:28514442
robust affinity purification-mass spectrometry methodology to elucidate protein interaction networks and co-complexes
GO:0005515 protein binding
IPI
PMID:29568061
An AP-MS- and BioID-compatible MAC-tag enables comprehensive...
MARK AS OVER ANNOTATED
Summary: Interaction (with HSPD1/P10809) detected using the MAC-tag AP-MS/BioID proximity-labeling platform. Bare "protein binding" from a high-throughput mapping method.
Reason: High-throughput proximity/AP-MS "protein binding" is uninformative for BCAT2 core function. Retained as an experimental IPI per policy but marked as over-annotation; the HSPD1/HSP60 association is consistent with the mitochondrial matrix chaperone environment rather than a specific functional interaction.
Supporting Evidence:
PMID:29568061
comprehensive mapping of protein interactions and subcellular localizations
GO:0005515 protein binding
IPI
PMID:33961781
Dual proteome-scale networks reveal cell-specific remodeling...
MARK AS OVER ANNOTATED
Summary: Interactions (HSPD1/P10809, YBEY/P58557) from the BioPlex 3.0 dual proteome-scale AP-MS interactome. Bare "protein binding" from a high-throughput screen.
Reason: Proteome-scale AP-MS "protein binding" is uninformative about BCAT2's molecular function. Retained as an experimental IPI per policy, marked as over-annotation.
Supporting Evidence:
PMID:33961781
cell-specific remodeling of the human interactome
GO:0005515 protein binding
IPI
PMID:40205054
Multimodal cell maps as a foundation for structural and func...
MARK AS OVER ANNOTATED
Summary: Interactions (HSPD1/P10809, YBEY/P58557) from a multimodal cell-map interactome dataset. Bare "protein binding" from a high-throughput mapping study.
Reason: High-throughput interactome "protein binding" is uninformative for BCAT2 core function. Retained as an experimental IPI per policy, marked as over-annotation.
Supporting Evidence:
PMID:40205054
Multimodal cell maps as a foundation for structural and functional genomics
GO:0005759 mitochondrial matrix
IEA
GO_REF:0000107
ACCEPT
Summary: Ensembl-Compara orthology IEA (from mouse) placing BCAT2 activity in the mitochondrial matrix, the specific compartment where BCAA transamination occurs.
Reason: Mitochondrial matrix is the correct, specific subcellular location for this soluble matrix enzyme, consistent with its cleaved transit peptide and TAS/Reactome annotations.
Supporting Evidence:
PMID:9165094
encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
GO:0006552 L-leucine catabolic process
IEA
GO_REF:0000107
ACCEPT
Summary: Ensembl-Compara orthology IEA (from mouse) for L-leucine catabolic process. BCAT2 initiates leucine catabolism by transamination to 4-methyl-2-oxopentanoate (KIC).
Reason: Leucine transamination (GO:0052654) is a core BCAT2 activity and the enzyme initiates leucine catabolism; the process annotation is appropriate and core.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0006574 L-valine catabolic process
IEA
GO_REF:0000107
ACCEPT
Summary: Ensembl-Compara orthology IEA (from mouse) for L-valine catabolic process. Duplicates the IBA valine-catabolism annotation; correct and core.
Reason: BCAT2 initiates valine catabolism; core biological process.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0097009 energy homeostasis
IEA
GO_REF:0000107
KEEP AS NON CORE
Summary: Ensembl-Compara orthology IEA (from mouse) for energy homeostasis. BCAA catabolism feeds acetyl-CoA/succinyl-CoA into the TCA cycle and BCAT2 loss alters energy expenditure in mice, but this is a broad downstream physiological consequence rather than the enzyme's molecular role.
Reason: Energy homeostasis is a general, pleiotropic downstream process to which BCAA catabolism contributes indirectly (e.g. BCAT2-knockout mice show increased energy expenditure). It is not the core enzymatic function; keep as non-core.
GO:0005739 mitochondrion
IDA
GO_REF:0000052
ACCEPT
Summary: Direct immunofluorescence localization (Human Protein Atlas) placing BCAT2 in the mitochondrion.
Reason: Experimental (IDA) immunofluorescence confirms mitochondrial localization, in agreement with all other evidence; matrix is the specific compartment.
GO:0005739 mitochondrion
ISS
GO_REF:0000024
ACCEPT
Summary: Sequence-similarity localization to mitochondrion, transferred from rat ortholog (O35854). Consistent with the transit peptide and experimental data.
Reason: Mitochondrial localization is firmly established across evidence types.
Supporting Evidence:
PMID:9165094
encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
GO:0009083 branched-chain amino acid catabolic process
IDA
PMID:8702755
Two yeast homologs of ECA39, a target for c-Myc regulation, ...
ACCEPT
Summary: Direct experimental evidence that BCAT2 participates in BCAA catabolism: BCAT activity toward leucine, isoleucine and valine was measured, and the human/yeast homologs encode the branched-chain aminotransferases initiating BCAA breakdown.
Reason: This is the core biological process of BCAT2, supported by direct enzymatic assays with all three BCAA substrates.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0050873 brown fat cell differentiation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: Sequence-similarity annotation transferred from mouse (O35855): BCAA catabolism supplies lipogenic acetyl-CoA that EP300/p300 uses to acetylate and inhibit PRDM16, preventing adipose browning. A real but indirect metabolic-signalling role, downstream of the catabolic function.
Reason: This links BCAT2 to a specific downstream developmental/metabolic output (brown fat differentiation) via acetyl-CoA supply and PRDM16 regulation. It is genuine (documented in mouse orthologs) but is a peripheral, indirect role rather than BCAT2's core enzymatic function; keep as non-core.
Supporting Evidence:
UniProtKB:O35855
acetyl-CoA derived from branched chain amino acid catabolism is used by EP300/p300 to acetylate and inhibit PRDM16, thereby preventing adipose tissue browning
GO:0004084 branched-chain-amino-acid:2-oxoglutarate transaminase activity
IDA
PMID:8702755
Two yeast homologs of ECA39, a target for c-Myc regulation, ...
ACCEPT
Summary: Direct experimental demonstration of branched-chain aminotransferase activity for the cloned mitochondrial enzyme, assayed with leucine, isoleucine and valine as substrates.
Reason: This is the core molecular function of BCAT2 (EC 2.6.1.42), established by direct enzymatic assay.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:1903444 negative regulation of brown fat cell differentiation
ISS
GO_REF:0000024
KEEP AS NON CORE
Summary: Sequence-similarity annotation transferred from mouse (MGI:1276534) for negative regulation of brown fat cell differentiation, via BCAA-catabolism-derived acetyl-CoA and EP300/PRDM16 signalling.
Reason: Same indirect brown-fat/PRDM16 axis as GO:0050873; a genuine downstream metabolic-signalling role documented in mouse but peripheral to BCAT2's core transaminase function. Keep as non-core.
Supporting Evidence:
UniProtKB:O35855
acetyl-CoA derived from branched chain amino acid catabolism is used by EP300/p300 to acetylate and inhibit PRDM16, thereby preventing adipose tissue browning
GO:0005739 mitochondrion
HTP
PMID:34800366
Quantitative high-confidence human mitochondrial proteome an...
ACCEPT
Summary: High-throughput proteomic assignment of BCAT2 to the high-confidence human mitochondrial proteome (MitoCoP).
Reason: Corroborates mitochondrial localization by an orthogonal high-throughput proteomics method, consistent with all other evidence.
Supporting Evidence:
PMID:34800366
defined a mitochondrial high-confidence proteome of >1,100 proteins (MitoCoP)
GO:0052654 L-leucine:2-oxoglutarate transaminase activity
IDA
PMID:8702755
Two yeast homologs of ECA39, a target for c-Myc regulation, ...
ACCEPT
Summary: Direct experimental demonstration of L-leucine transaminase activity for the mitochondrial branched-chain aminotransferase.
Reason: Core substrate-specific molecular function, directly measured with leucine as substrate.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0052655 L-valine:2-oxoglutarate transaminase activity
IDA
PMID:8702755
Two yeast homologs of ECA39, a target for c-Myc regulation, ...
ACCEPT
Summary: Direct experimental demonstration of L-valine transaminase activity for the mitochondrial branched-chain aminotransferase.
Reason: Core substrate-specific molecular function, directly measured with valine as substrate.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0052656 L-isoleucine:2-oxoglutarate transaminase activity
IDA
PMID:8702755
Two yeast homologs of ECA39, a target for c-Myc regulation, ...
ACCEPT
Summary: Direct experimental demonstration of L-isoleucine transaminase activity for the mitochondrial branched-chain aminotransferase.
Reason: Core substrate-specific molecular function, directly measured with isoleucine as substrate.
Supporting Evidence:
PMID:8702755
Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
GO:0005759 mitochondrial matrix
TAS
Reactome:R-HSA-508179
ACCEPT
Summary: Reactome traceable-author-statement placing the BCAT2 reaction in the mitochondrial matrix (reverse direction: keto acids + glutamate to BCAAs + alpha-ketoglutarate).
Reason: Mitochondrial matrix is the correct specific location for this enzyme; Reactome annotation is consistent with all other evidence.
GO:0005759 mitochondrial matrix
TAS
Reactome:R-HSA-70724
ACCEPT
Summary: Reactome traceable-author-statement placing the BCAT2 reaction in the mitochondrial matrix (forward catabolic direction: BCAAs + alpha-ketoglutarate to keto acids + glutamate).
Reason: Mitochondrial matrix is the correct specific location for this enzyme; consistent with all other evidence.
GO:0004084 branched-chain-amino-acid:2-oxoglutarate transaminase activity
TAS
PMID:9165094
Cloning of the rat and human mitochondrial branched chain am...
ACCEPT
Summary: Traceable author statement (cloning of rat and human BCATm) supporting the branched-chain aminotransferase molecular function. This paper established the BCAT1/BCAT2 nomenclature and showed the cloned enzyme has BCAT activity.
Reason: Corroborates the core EC-level molecular function of BCAT2 with TAS from the defining cloning paper.
Supporting Evidence:
PMID:9165094
the protein exhibits BCAT activity and correct processing of the mitochondrial targeting sequence
GO:0005739 mitochondrion
TAS
PMID:9165094
Cloning of the rat and human mitochondrial branched chain am...
ACCEPT
Summary: Traceable author statement for mitochondrial localization from the BCATm cloning paper, which demonstrated correct processing of the mitochondrial targeting presequence.
Reason: Mitochondrial localization is established; the cloning paper showed proper mitochondrial targeting-sequence processing.
Supporting Evidence:
PMID:9165094
the protein exhibits BCAT activity and correct processing of the mitochondrial targeting sequence
GO:0009082 branched-chain amino acid biosynthetic process
TAS
PMID:8702755
Two yeast homologs of ECA39, a target for c-Myc regulation, ...
MARK AS OVER ANNOTATED
Summary: Older TAS annotating branched-chain amino acid BIOSYNTHETIC process, presumably reflecting the chemically reversible transamination. In humans BCAAs are essential and not synthesized de novo, so the physiological direction is catabolic.
Reason: The reversible reaction can re-aminate branched-chain keto acids, but net BCAA biosynthesis is a microbial/plant role of BCAT-family enzymes, not the human function; humans require dietary BCAAs. The biosynthetic-process annotation over-states the in vivo role. Retained as an over-annotation (the reversible chemistry is real) rather than removed.
Supporting Evidence:
PMID:8702755
code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
GO:0030170 pyridoxal phosphate binding
IDA
PMID:8702755
Two yeast homologs of ECA39, a target for c-Myc regulation, ...
NEW
Summary: Proposed annotation (not in current GOA): BCAT2 binds pyridoxal 5'-phosphate (PLP) as its essential catalytic cofactor. UniProt records PLP as the cofactor (COFACTOR, from crystallographic studies) and a Schiff-base MOD_RES at Lys-229; PLP binding is required for the demonstrated aminotransferase activity.
Reason: PLP-binding is a well-established, structurally and biochemically documented molecular function of this class-IV PLP-dependent aminotransferase (many BCATm crystal structures resolve the PLP cofactor; the Schiff-base lysine is annotated in UniProt) and directly underlies its catalytic activity. It is currently missing from GOA and is added here as a core function.
Supporting Evidence:
file:human/BCAT2/BCAT2-uniprot.txt
Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;

Core Functions

BCAT2 is the mitochondrial branched-chain-amino-acid aminotransferase (EC 2.6.1.42) that catalyzes the first, reversible step of branched-chain amino acid catabolism: PLP-dependent transamination of L-leucine, L-isoleucine and L-valine with 2-oxoglutarate to give the corresponding branched-chain 2-oxo acids (KIC, KMV, KIV) plus L-glutamate, feeding the products to the mitochondrial BCKDH complex. It acts as a homodimer in the mitochondrial matrix.

Supporting Evidence:
  • PMID:8702755
    Activity of branched-chain amino acid aminotransferase was measured in the wild-type and mutants with either leucine, isoleucine, or valine as substrates
  • PMID:9165094
    the protein exhibits BCAT activity and correct processing of the mitochondrial targeting sequence

Catalysis requires the cofactor pyridoxal 5'-phosphate (PLP), which is bound at the active site via a Schiff-base (internal aldimine) linkage to Lys-229 and cycles between the aldimine (PLP) and pyridoxamine (PMP) forms during the ping-pong transamination mechanism. PLP binding is essential for BCAT2 aminotransferase activity, and the disease-relevant loss of activity can be partially rescued by vitamin B6 (PLP precursor) supplementation.

References

file:human/BCAT2/BCAT2-deep-research-falcon.md
Deep research report on BCAT2 (falcon/Edison)
Gene Ontology annotation through association of InterPro records with GO terms
Manual transfer of experimentally-verified manual GO annotation data to orthologs by curator judgment of sequence similarity
Annotation inferences using phylogenetic trees
Gene Ontology annotation based on curation of immunofluorescence data
Automatic transfer of experimentally verified manual GO annotation data to orthologs using Ensembl Compara
Automatic Gene Ontology annotation based on Rhea mapping
Electronic Gene Ontology annotations created by ARBA machine learning models
Combined Automated Annotation using Multiple IEA Methods
Architecture of the human interactome defines protein communities and disease networks.
An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein interactions and subcellular localizations.
Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context.
Multimodal cell maps as a foundation for structural and functional genomics.
Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases.
Cloning of the rat and human mitochondrial branched chain aminotransferases (BCATm).
Reactome:R-HSA-508179
a-ketoisocaproate, a-keto-b-methylvalerate, or a-ketoisovalerate + glutamate
Reactome:R-HSA-70724
leu, ile, or val + alpha-ketoglutarate <=> a-ketoisocaproate, a-keto-b-methylvalerate,
UniProtKB:O35855
Branched-chain-amino-acid aminotransferase, mitochondrial (Mus musculus)

Suggested Questions for Experts

Q: In human tissues, does BCAT2 carry any physiologically relevant biosynthetic (re-amination) flux toward BCAAs, or is the net direction exclusively catabolic given the essentiality of dietary BCAAs?

Q: To what extent do the reported BCAT2 protein-protein interactions (e.g. with HSPD1/HSP60) and the CXXC-dependent metabolon with the BCKDH E1 subunit represent discrete functional partnerships versus co-purification within the mitochondrial matrix?

Suggested Experiments

Experiment: Quantify BCAA-to-BCKA flux directionality in situ (e.g. stable-isotope 15N/13C tracing) in BCAT2-expressing human muscle vs liver models to determine whether any net biosynthetic re-amination occurs physiologically.

Experiment: Reconstitute the BCAT2-BCKDH E1 metabolon in vitro with reduced vs oxidized CXXC-center BCAT2 (and C342A/C345A mutants) to test how the redox state of the CXXC center gates substrate channeling and overall BCAA oxidation rate.

Deep Research

Falcon

(BCAT2-deep-research-falcon.md)
Comprehensive Research Report: BCAT2 (Branched-Chain Amino Acid Aminotransferase 2, Mitochondrial) Falcon Edison Scientific Literature 46 citations 2 artifacts 2026-07-05T19:56:21.996993

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: BCAT2 (Branched-Chain Amino Acid Aminotransferase 2, Mitochondrial)

Gene: BCAT2 (also known as BCATM, BCT2, ECA40) | UniProt: O15382 | Organism: Homo sapiens | EC: 2.6.1.42 | Chromosomal Location: 19q13.33


1. Gene Identity and Protein Description

BCAT2 encodes the mitochondrial isoform of the branched-chain aminotransferase (also designated BCATm), a pyridoxal-5'-phosphate (PLP)-dependent enzyme that catalyzes the first step in the catabolism of the three branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 7-9). The protein is synthesized as a precursor containing a mitochondrial targeting sequence that is cleaved upon import into the mitochondrial matrix (conway2021emergingmoonlightingfunctions pages 3-5). BCAT2 is distinguished from its paralog BCAT1 (BCATc), which is cytosolic and exhibits restricted tissue expression primarily in neuronal tissues (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 3-5). The two isoforms share approximately 58% sequence identity and have nearly identical active sites, yet differ fundamentally in subcellular localization, tissue distribution, and regulatory properties (conway2021emergingmoonlightingfunctions pages 9-11).

The following table summarizes the key distinctions between the two human BCAT isoforms:

Isoform Gene name Protein name Subcellular localization Tissue expression Chromosomal location Key structural features PDB code Role in disease
BCAT1 BCAT1 Branched-chain-amino-acid aminotransferase, cytosolic (BCATc) Cytosol (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 3-5) Restricted; enriched in neuronal tissues (brain, spinal cord, retina), and also ovary, testes, placenta, pancreas (bo2024primaryrolesof pages 9-11) Not established from gathered evidence Redox-active CXXC motif C335/C338; PLP-dependent active site with catalytic lysine reported as Lys222 in structural evidence (conway2021emergingmoonlightingfunctions pages 13-15, conway2021emergingmoonlightingfunctions pages 47-51) 2COJ (conway2021emergingmoonlightingfunctions pages 47-51) Prominent in neurologic/glutamate metabolism; aberrantly expressed in several cancers and linked to tumor progression; bi-allelic variants reported in candidate neurometabolic disorder literature retrieved during search (sperringer2017branchedchainaminoacids pages 6-7, conway2021emergingmoonlightingfunctions pages 7-9)
BCAT2 BCAT2 Branched-chain-amino-acid aminotransferase, mitochondrial (BCATm); also called placental protein 18/PP18 in older nomenclature Mitochondria (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 3-5) Broad/ubiquitous; highest in skeletal muscle, colon, kidney, pancreas; low in liver (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 3-5) 19q13.33 (conway2021emergingmoonlightingfunctions pages 3-5) Redox-active CXXC motif C315/C318; PLP-dependent active site with catalytic lysine reported as Lys202 in BCATm crystal structure; functions as homodimer (conway2021emergingmoonlightingfunctions pages 11-13, knerr2019expandingthegenetic pages 2-4, conway2021emergingmoonlightingfunctions pages 47-51) 1EKF (reduced form); additional BCATm forms 1KTA, 1KT8 (knerr2019expandingthegenetic pages 2-4, conway2021emergingmoonlightingfunctions pages 47-51, conway2021emergingmoonlightingfunctions pages 13-15) Causal gene for ultra-rare BCAT2 deficiency with elevated plasma BCAAs and low/normal BCKAs; also implicated in cancer metabolism, ferroptosis resistance, pancreatic cancer growth, melanoma progression, prostate cancer survival signaling, and metabolic disease/insulin-resistance pathways (wang2021branchedchainaminoacid pages 1-2, lei2020acetylationpromotesbcat2 pages 5-7, knerr2019expandingthegenetic pages 5-7, knerr2019expandingthegenetic pages 7-8, bo2024primaryrolesof pages 18-19, bo2024primaryrolesof pages 11-13)

Table: This table compares the human BCAT1 and BCAT2 isoforms across localization, tissue expression, structural features, and disease relevance. It is useful for distinguishing the cytosolic neuronal isoform from the mitochondrial broadly expressed isoform central to BCAA catabolism.


2. Enzymatic Function and Catalytic Mechanism

2.1. Reaction Catalyzed

BCAT2 catalyzes the reversible transamination of all three BCAAs with α-ketoglutarate (2-oxoglutarate) as the amino group acceptor, producing the corresponding branched-chain α-keto acids (BCKAs) and L-glutamate (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 7-9). Specifically, leucine is converted to α-ketoisocaproate (KIC), isoleucine to α-keto-β-methylvalerate (KMV), and valine to α-ketoisovalerate (KIV) (bo2024primaryrolesof pages 9-11). The enzyme shows no strong discrimination among the three BCAAs, acting on all three substrates with comparable catalytic efficiency (bo2024primaryrolesof pages 9-11).

2.2. Cofactor and Mechanism

The reaction requires pyridoxal-5'-phosphate (PLP, a vitamin B6 derivative) as an essential cofactor, which is covalently bound to the enzyme via a Schiff base (internal aldimine) linkage with a conserved lysine residue (Lys202 in BCATm) (conway2021emergingmoonlightingfunctions pages 47-51, conway2021emergingmoonlightingfunctions pages 7-9). The catalytic cycle proceeds through a classical ping-pong (bi-bi) kinetic mechanism comprising two half-reactions (conway2021emergingmoonlightingfunctions pages 7-9). In the first half-reaction, the amino acid substrate displaces the active site lysine from the PLP cofactor through transaldimination, forming an external aldimine between the substrate and PLP. A subsequent 1,3-prototropic shift, in which the lysine residue acts as a catalytic base, generates a ketimine intermediate. Hydrolysis of this intermediate releases the α-keto acid product and converts PLP to pyridoxamine phosphate (PMP) (conway2021emergingmoonlightingfunctions pages 7-9). The second half-reaction proceeds in reverse with α-ketoglutarate as substrate, regenerating PLP and producing glutamate (conway2021emergingmoonlightingfunctions pages 7-9).

2.3. Substrate Specificity and Reversibility

The reaction is thermodynamically near equilibrium and fully reversible, meaning BCAT2 can also catalyze the re-amination of BCKAs to BCAAs (knerr2019expandingthegenetic pages 2-4, bo2024primaryrolesof pages 9-11). This reversibility has physiological significance: in tissues such as the brain, BCAT isoforms participate in a BCAA-BCKA nitrogen shuttle cycle that contributes to glutamate neurotransmitter synthesis (sperringer2017branchedchainaminoacids pages 6-7, sperringer2017branchedchainaminoacids pages 4-6).


3. Protein Structure

3.1. Overall Architecture

The crystal structure of human BCAT2 (BCATm) has been resolved (PDB: 1EKF in the reduced form; additional structures 1KTA and 1KT8 represent the pyridoxamine and ketimine intermediate forms, respectively) (knerr2019expandingthegenetic pages 2-4, conway2021emergingmoonlightingfunctions pages 47-51, conway2021emergingmoonlightingfunctions pages 13-15). BCAT2 functions as a homodimer, with each monomer consisting of a small domain (approximately residues 1–175) and a large domain (residues 176–365), connected by an interdomain loop (conway2021emergingmoonlightingfunctions pages 9-11). Two PLP cofactors are positioned at the dimer interface, each within an active site (conway2021emergingmoonlightingfunctions pages 9-11, knerr2019expandingthegenetic pages 2-4). The substrate-binding pocket is lined with hydrophobic residues including Tyr207, Phe75, and Tyr70, which create a favorable environment for anchoring the branched aliphatic side chains of the BCAA substrates (conway2021emergingmoonlightingfunctions pages 9-11).

3.2. The CXXC Redox Motif

A unique and functionally critical feature of BCAT proteins is a conserved CXXC redox-active motif (C315 and C318 in BCATm) located near the active site (conway2021emergingmoonlightingfunctions pages 11-13, conway2021emergingmoonlightingfunctions pages 47-51). The N-terminal cysteine (C315) serves as the redox sensor, while C318 functions as the resolving cysteine, enabling reversible regulation through thiol-disulfide interconversion (conway2021emergingmoonlightingfunctions pages 13-15, conway2021emergingmoonlightingfunctions pages 11-13). Oxidation by hydrogen peroxide causes a dose-dependent loss of enzymatic activity, with up to 4-fold reductions in kcat and 5–10-fold increases in Kd for BCAA substrates (conway2021emergingmoonlightingfunctions pages 11-13). Reduced thioredoxin can partially restore activity after oxidation, indicating redox cycling capability (conway2021emergingmoonlightingfunctions pages 11-13). Beyond regulating aminotransferase activity, the CXXC motif endows BCAT with a novel thiol oxidoreductase/chaperone function: oxidized BCAT proteins can catalyze dithiol-disulfide exchange reactions similar to protein disulfide isomerases (PDIs), facilitating insertion of disulfide bonds into substrate proteins (conway2021emergingmoonlightingfunctions pages 17-19, conway2021emergingmoonlightingfunctions pages 1-3, conway2021emergingmoonlightingfunctions pages 55-56). BCATm has been shown to co-localize with PDI and Mia40 in the mitochondrial intermembrane space, supporting a moonlighting role as a redox-active chaperone involved in protein folding (conway2021emergingmoonlightingfunctions pages 55-56).


4. Subcellular Localization and Tissue Expression

BCAT2 is a mitochondrial matrix protein, consistent with its role in the initial catabolism of BCAAs within this organelle (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 3-5). Its expression is ubiquitous across most human tissues, with particularly high levels in skeletal muscle, colon, kidney, and pancreas, and notably low expression in the liver (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 3-5). This tissue distribution is functionally significant: because BCAT2 expression is high in muscle but low in liver, skeletal muscle serves as the primary site of BCAA transamination, while the liver—which expresses abundant BCKDH but little BCAT2—preferentially oxidizes the muscle-derived BCKAs (bo2024primaryrolesof pages 9-11, sperringer2017branchedchainaminoacids pages 4-6). This inter-organ division of labor underlies the efficient systemic catabolism of BCAAs.


5. Biochemical Pathway Context and Metabolon Formation

5.1. The BCAA Catabolic Pathway

BCAT2 catalyzes the first step in mitochondrial BCAA catabolism. The second and rate-limiting committed step is performed by the branched-chain α-ketoacid dehydrogenase (BCKDH) complex, a multienzyme assembly (E1, E2, E3) that catalyzes the irreversible oxidative decarboxylation of BCKAs to their corresponding branched-chain acyl-CoA derivatives (isovaleryl-CoA from leucine, 2-methylbutyryl-CoA from isoleucine, isobutyryl-CoA from valine) (bo2024primaryrolesof pages 11-13, mei2026branchedchainaminoacids pages 3-5, conway2021emergingmoonlightingfunctions pages 47-51). These acyl-CoA products are further metabolized through dedicated pathways to produce acetyl-CoA and/or succinyl-CoA, which enter the TCA cycle (mei2026branchedchainaminoacids pages 3-5, sperringer2017branchedchainaminoacids pages 2-4). The BCKDH complex is regulated by a phosphorylation–dephosphorylation cycle: BCKDK (branched-chain ketoacid dehydrogenase kinase) phosphorylates and inactivates BCKDH, whereas PPM1K (protein phosphatase 2Cm) dephosphorylates and activates it (mei2026branchedchainaminoacids pages 3-5, sperringer2017branchedchainaminoacids pages 4-6).

The following table summarizes the pathway steps:

Step number Enzyme Reaction Substrates Products Compartment Regulatory mechanism
1 BCAT2 (branched-chain amino acid aminotransferase, mitochondrial) Reversible PLP-dependent transamination of branched-chain amino acids to branched-chain α-keto acids (BCKAs) Leucine, isoleucine, valine + α-ketoglutarate 2-ketoisocaproate (KIC), 2-keto-3-methylvalerate (KMV), 2-ketoisovalerate (KIV) + glutamate Mitochondria, especially in extrahepatic tissues such as skeletal muscle Requires PLP cofactor; activity is redox-sensitive via the CXXC motif (C315/C318), where oxidation decreases activity and alters substrate affinity; BCAT2 can physically associate with BCKDH to support substrate channeling; BCAT2 stability is regulated by K44 acetylationCBP promotes acetylation and ubiquitin-proteasome degradation, whereas SIRT4 deacetylates and stabilizes BCAT2 (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 7-9, conway2021emergingmoonlightingfunctions pages 11-13, conway2021emergingmoonlightingfunctions pages 15-17, lei2020acetylationpromotesbcat2 pages 5-7, lei2020acetylationpromotesbcat2 pages 4-5, lei2020acetylationpromotesbcat2 pages 2-4)
2 BCKDH complex (branched-chain α-ketoacid dehydrogenase; E1/E2/E3) Oxidative decarboxylation of BCKAs to branched-chain acyl-CoA derivatives; committed/rate-limiting step of BCAA oxidation KIC, KMV, KIV Isovaleryl-CoA, 2-methylbutyryl-CoA, isobutyryl-CoA + reducing equivalents Mitochondrial matrix Activity is inhibited by BCKDK-mediated phosphorylation and activated by PPM1K-mediated dephosphorylation; BCAT2 interaction with BCKDH supports metabolon formation and efficient transfer of BCKA products; BCAT2 loss can abolish effective BCKDH function in this pathway context (bo2024primaryrolesof pages 11-13, mei2026branchedchainaminoacids pages 3-5, conway2021emergingmoonlightingfunctions pages 47-51, sperringer2017branchedchainaminoacids pages 4-6, sperringer2017branchedchainaminoacids pages 2-4)
3 Downstream BCAA oxidation enzymes (multiple acyl-CoA dehydrogenation/hydration/cleavage steps) Conversion of branched-chain acyl-CoA intermediates to central carbon metabolites that feed the TCA cycle Isovaleryl-CoA, 2-methylbutyryl-CoA, isobutyryl-CoA and subsequent intermediates Acetyl-CoA and/or succinyl-CoA (depending on BCAA species), which enter the TCA cycle for energy metabolism and biosynthesis Mitochondria Flux through this stage depends on upstream BCAT2/BCKDH activity and whole-pathway control of BCAA catabolism; impaired upstream catabolism contributes to BCAA/BCKA accumulation linked to metabolic disease, while intact downstream oxidation supports mitochondrial energy production and metabolic flexibility (mei2026branchedchainaminoacids pages 3-5, conway2021emergingmoonlightingfunctions pages 47-51, sperringer2017branchedchainaminoacids pages 2-4, bo2024primaryrolesof pages 18-19, bo2024primaryrolesof pages 11-13)

Table: This table summarizes the core mitochondrial steps of branched-chain amino acid catabolism involving BCAT2, from transamination through BCKDH-mediated oxidation to TCA cycle entry. It also highlights the main regulatory layers controlling pathway flux, including redox regulation, post-translational control of BCAT2, and BCKDH phosphorylation status.

5.2. Metabolon Formation and Substrate Channeling

BCAT2 and the BCKDH complex physically interact within the mitochondrial matrix to form a metabolon that enables substrate channeling (conway2021emergingmoonlightingfunctions pages 15-17, bo2024primaryrolesof pages 11-13). For this interaction, BCATm must be in its reduced PLP form and adopt an open conformation; the PLP-bound form of BCATm binds directly to the E1α subunit of BCKDH, increasing the kinetic rate of BCKA decarboxylation (conway2021emergingmoonlightingfunctions pages 15-17). After transamination converts BCATm-PLP to BCATm-PMP, the enzyme is released from E1 (conway2021emergingmoonlightingfunctions pages 15-17). Critically, when BCAT2 is absent, BCKDH activity is effectively abolished, demonstrating the functional dependence of efficient BCAA oxidation on this protein–protein interaction (bo2024primaryrolesof pages 11-13). BCATm may also interact with glutamate dehydrogenase (GDH) for regeneration of α-ketoglutarate, completing the metabolic cycle (conway2021emergingmoonlightingfunctions pages 15-17). Oxidation of the CXXC motif or mutation of the reactive cysteines prevents metabolon formation (conway2021emergingmoonlightingfunctions pages 15-17).

5.3. Role in Nitrogen Metabolism

BCAT proteins serve as critical nitrogen donors in interorgan and intercellular nitrogen shuttling (sperringer2017branchedchainaminoacids pages 1-2). In the brain, BCAAs readily cross the blood–brain barrier and contribute approximately 20–30% of brain glutamate synthesis, the major excitatory neurotransmitter (sperringer2017branchedchainaminoacids pages 6-7, conway2021emergingmoonlightingfunctions pages 7-9, conway2021emergingmoonlightingfunctions pages 5-7). In rodent models, a BCAA-BCKA shuttle cycle operates between astrocytes and neurons: BCATm in astrocytes transaminates leucine to produce KIC and glutamate; KIC is released and taken up by neurons, where BCATc re-aminates it with glutamate, regenerating leucine and supporting neurotransmitter pools (sperringer2017branchedchainaminoacids pages 6-7, sperringer2017branchedchainaminoacids pages 4-6). In the human brain, BCATm is localized to capillary endothelial cells rather than astrocytes, suggesting species-specific differences in this shuttle mechanism (sperringer2017branchedchainaminoacids pages 6-7, conway2021emergingmoonlightingfunctions pages 7-9).


6. Post-Translational Regulation of BCAT2

6.1. Acetylation at Lysine 44

BCAT2 protein stability is regulated by acetylation at the evolutionarily conserved residue lysine 44 (K44). The acetyltransferase CBP (CREB-binding protein) catalyzes K44 acetylation, which promotes BCAT2 ubiquitination and degradation through the ubiquitin–proteasome pathway (lei2020acetylationpromotesbcat2 pages 5-7, lei2020acetylationpromotesbcat2 pages 4-5, lei2020acetylationpromotesbcat2 pages 2-4). The mitochondrial sirtuin SIRT4 opposes this modification by deacetylating K44, stabilizing BCAT2 protein levels (lei2020acetylationpromotesbcat2 pages 5-7, lei2020acetylationpromotesbcat2 pages 4-5). Importantly, K44 acetylation does not directly affect BCAT2 enzymatic activity but controls protein abundance (lei2020acetylationpromotesbcat2 pages 2-4). BCAA deprivation stimulates K44 acetylation, providing a nutrient-sensing feedback mechanism that links amino acid availability to BCAT2 degradation (lei2020acetylationpromotesbcat2 pages 1-2, lei2020acetylationpromotesbcat2 pages 2-4). A non-acetylatable K44R mutant is more stable, promotes increased BCAA catabolism, and enhances pancreatic tumor growth in vivo (lei2020acetylationpromotesbcat2 pages 5-7, lei2020acetylationpromotesbcat2 pages 1-2).

6.2. Additional Post-Translational Modifications

Beyond acetylation, BCAT2 stability is regulated by deubiquitination at K229 mediated by USP1, and by phosphorylation at Y228 through a KRAS-SYK-TRIM21 signaling axis—both mechanisms contributing to BCAT2 stabilization in pancreatic cancer (zhang2026branchedchainaminoacid pages 4-5).


7. Disease Associations

7.1. BCAT2 Deficiency (Inborn Error of Metabolism)

BCAT2 deficiency (MIM 113530) is an ultra-rare autosomal recessive inborn error of BCAA catabolism caused by biallelic loss-of-function mutations in BCAT2 (knerr2019expandingthegenetic pages 5-7, knerr2019expandingthegenetic pages 1-2). The biochemical hallmark is markedly elevated plasma BCAAs—with disproportionately high valine levels—combined with low-normal or undetectable BCKAs and absent L-allo-isoleucine, clearly distinguishing it from maple syrup urine disease (MSUD), which shows elevation of both BCAAs and BCKAs (knerr2019expandingthegenetic pages 5-7, knerr2019expandingthegenetic pages 7-8, knerr2019expandingthegenetic pages 2-4). Knerr et al. (2019) characterized five individuals from four families with homozygous or compound heterozygous BCAT2 mutations, reporting that clinical phenotypes ranged from asymptomatic adulthood to developmental delay, intellectual disability, speech impairment, and autism spectrum features (knerr2019expandingthegenetic pages 5-7, knerr2019expandingthegenetic pages 7-8). Notably, unlike MSUD, no individual with BCAT2 deficiency developed acute encephalopathy even with exceptionally elevated BCAA levels (knerr2019expandingthegenetic pages 7-8, knerr2019expandingthegenetic pages 1-2). The authors suggested that the neurodevelopmental phenotype may relate to disturbed glutamate and GABA homeostasis, since BCAAs serve as nitrogen donors for these neurotransmitters (knerr2019expandingthegenetic pages 8-9). Western blot analysis demonstrated absent BCAT2 protein in some patients, and fibroblast studies confirmed markedly reduced leucine and valine decarboxylation capacity (knerr2019expandingthegenetic pages 4-5). Dietary protein restriction and pyridoxine supplementation appeared to reduce BCAA levels (knerr2019expandingthegenetic pages 4-5, haydar2018branchedchainamino pages 2-4).

7.2. Cancer

BCAT2 has emerged as a significant player in cancer metabolism with context-dependent roles across multiple tumor types. In pancreatic ductal adenocarcinoma (PDAC), BCAT2 is consistently upregulated and its expression is stabilized by KRAS-dependent mechanisms; knockdown suppresses tumor growth both in vitro and in vivo (he2026bcaasandrelated pages 7-8, lei2020acetylationpromotesbcat2 pages 5-7, zhang2026branchedchainaminoacid pages 4-5). In hepatocellular carcinoma, BCAT2 was identified through a genome-wide CRISPR/Cas9 screen as a novel suppressor of ferroptosis: BCAT2 regulates intracellular glutamate levels and antagonizes system Xc⁻ inhibition, protecting cancer cells from ferroptotic death induced by sorafenib and erastin (wang2021branchedchainaminoacid pages 1-2). Ferroptosis inducers activate the AMPK/SREBP1 signaling pathway, which inhibits BCAT2 transcription, and co-treatment with sorafenib and sulfasalazine synergistically downregulates BCAT2 to trigger ferroptosis (wang2021branchedchainaminoacid pages 1-2). In melanoma, BCAT2 promotes lipogenesis by regulating FASN and ACLY expression through P300-dependent histone acetylation, with ZEB1 acting as an upstream transcriptional activator (zhang2026branchedchainaminoacid pages 13-14, zhang2026branchedchainaminoacid pages 15-17). In prostate cancer, BCAT2 inhibits autophagy-dependent apoptosis and ferroptosis through interaction with PCBP1 at Leucine 239 to co-regulate the PI3K/AKT signaling pathway (zhang2026branchedchainaminoacid pages 13-14, zhang2026branchedchainaminoacid pages 11-13, zhang2026branchedchainaminoacid pages 15-17). In bladder cancer, BCAT2 suppresses cytotoxic T-cell recruitment, creating an immunosuppressive tumor microenvironment; inhibiting BCAT2 synergizes with anti-PD-1 therapy (zhang2026branchedchainaminoacid pages 13-14). BCAT1 and BCAT2 exhibit a transcriptional compensatory relationship that together maintains BCAA catabolic stability in tumors (zhang2026branchedchainaminoacid pages 11-13).

7.3. Diabetes and Metabolic Disease

Elevated circulating BCAA levels are a consistent and predictive biomarker of insulin resistance and type 2 diabetes mellitus (T2DM) (conway2021emergingmoonlightingfunctions pages 5-7, mei2026branchedchainaminoacids pages 5-6, mei2026branchedchainaminoacids pages 1-2). Impaired BCAT2-mediated BCAA catabolism in skeletal muscle and adipose tissue contributes to this elevation, leading to sustained mTORC1 activation, serine phosphorylation of IRS-1, and attenuation of insulin signaling (mei2026branchedchainaminoacids pages 5-6, mei2026branchedchainaminoacids pages 2-3). In BCAT2-knockout mice, blood BCAA concentrations increase more than 10-fold, though paradoxically, body weight and adiposity decrease due to increased energy expenditure (bo2024primaryrolesof pages 11-13). The compound BT2, which inhibits BCKDK and thereby reactivates the BCKDH complex, has been shown to reduce circulating BCAAs and potentiate metformin's glucose-lowering effects in obese mice (mei2026branchedchainaminoacids pages 6-8). Recent work has also implicated BCAT2 in diabetic atherosclerotic calcification, where BCAT2 is upregulated in vascular smooth muscle cells and its catabolism of BCAAs to BCKAs promotes osteogenic differentiation through BCKA-derived propionyl-CoA and histone propionylation at the RUNX2 promoter (Zhang et al., 2026).


8. Summary

BCAT2 is the ubiquitously expressed, mitochondrial isoform of branched-chain amino acid aminotransferase that catalyzes the reversible, PLP-dependent transamination of leucine, isoleucine, and valine to their corresponding branched-chain α-keto acids, with concomitant conversion of α-ketoglutarate to glutamate (bo2024primaryrolesof pages 9-11, conway2021emergingmoonlightingfunctions pages 7-9). It functions within the mitochondrial matrix, where it physically associates with the BCKDH complex in a metabolon that enables efficient substrate channeling and complete BCAA oxidation (conway2021emergingmoonlightingfunctions pages 15-17, bo2024primaryrolesof pages 11-13). Its activity is regulated at multiple levels: at the cofactor level by PLP availability, at the protein level by redox-sensitive CXXC motif oxidation (C315/C318), and at the stability level by K44 acetylation mediated by CBP/SIRT4 (conway2021emergingmoonlightingfunctions pages 11-13, lei2020acetylationpromotesbcat2 pages 5-7). BCAT2 deficiency is an ultra-rare inborn error of metabolism characterized by elevated BCAAs with low BCKAs and variable neurodevelopmental phenotypes (knerr2019expandingthegenetic pages 5-7, knerr2019expandingthegenetic pages 1-2). In the broader disease context, BCAT2 has emerged as a nexus between amino acid metabolism and cancer biology—regulating ferroptosis sensitivity, tumor proliferation, and immune evasion in a cancer type-dependent manner—and as a contributor to BCAA-mediated insulin resistance in metabolic disease (he2026bcaasandrelated pages 7-8, wang2021branchedchainaminoacid pages 1-2, conway2021emergingmoonlightingfunctions pages 5-7, mei2026branchedchainaminoacids pages 5-6).

References

  1. (bo2024primaryrolesof pages 9-11): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.

  2. (conway2021emergingmoonlightingfunctions pages 7-9): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  3. (conway2021emergingmoonlightingfunctions pages 3-5): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  4. (conway2021emergingmoonlightingfunctions pages 9-11): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  5. (conway2021emergingmoonlightingfunctions pages 13-15): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  6. (conway2021emergingmoonlightingfunctions pages 47-51): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  7. (sperringer2017branchedchainaminoacids pages 6-7): Justin E. Sperringer, Adele Addington, and Susan M. Hutson. Branched-chain amino acids and brain metabolism. Neurochemical Research, 42:1697-1709, Apr 2017. URL: https://doi.org/10.1007/s11064-017-2261-5, doi:10.1007/s11064-017-2261-5. This article has 265 citations and is from a peer-reviewed journal.

  8. (conway2021emergingmoonlightingfunctions pages 11-13): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  9. (knerr2019expandingthegenetic pages 2-4): Ina Knerr, Roberto Colombo, Jill Urquhart, Ana Morais, Begona Merinero, Alfonso Oyarzabal, Belén Pérez, Simon A. Jones, Rahat Perveen, Mary A. Preece, Yvonne Rogers, Eileen P. Treacy, Philip Mayne, Giuseppe Zampino, Sabrina MacKinnon, Evangeline Wassmer, Wyatt W. Yue, Ian Robinson, Pilar Rodríguez‐Pombo, Simon E. Olpin, and Siddharth Banka. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. Journal of Inherited Metabolic Disease, 42:809-817, Aug 2019. URL: https://doi.org/10.1002/jimd.12135, doi:10.1002/jimd.12135. This article has 32 citations and is from a peer-reviewed journal.

  10. (wang2021branchedchainaminoacid pages 1-2): Kang Wang, Zhengyang Zhang, Hsiang-i Tsai, Yanfang Liu, Jie Gao, Ming Wang, Lian Song, Xiongfeng Cao, Zhanxue Xu, Hongbo Chen, Aihua Gong, Dongqing Wang, Fang Cheng, and Haitao Zhu. Branched-chain amino acid aminotransferase 2 regulates ferroptotic cell death in cancer cells. Cell Death & Differentiation, 28:1222-1236, Oct 2021. URL: https://doi.org/10.1038/s41418-020-00644-4, doi:10.1038/s41418-020-00644-4. This article has 218 citations and is from a domain leading peer-reviewed journal.

  11. (lei2020acetylationpromotesbcat2 pages 5-7): Ming-Zhu Lei, Xu-Xu Li, Ye Zhang, Jin-Tao Li, Fan Zhang, Yi-Ping Wang, Miao Yin, Jia Qu, and Qun-Ying Lei. Acetylation promotes bcat2 degradation to suppress bcaa catabolism and pancreatic cancer growth. Signal Transduction and Targeted Therapy, May 2020. URL: https://doi.org/10.1038/s41392-020-0168-0, doi:10.1038/s41392-020-0168-0. This article has 132 citations and is from a peer-reviewed journal.

  12. (knerr2019expandingthegenetic pages 5-7): Ina Knerr, Roberto Colombo, Jill Urquhart, Ana Morais, Begona Merinero, Alfonso Oyarzabal, Belén Pérez, Simon A. Jones, Rahat Perveen, Mary A. Preece, Yvonne Rogers, Eileen P. Treacy, Philip Mayne, Giuseppe Zampino, Sabrina MacKinnon, Evangeline Wassmer, Wyatt W. Yue, Ian Robinson, Pilar Rodríguez‐Pombo, Simon E. Olpin, and Siddharth Banka. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. Journal of Inherited Metabolic Disease, 42:809-817, Aug 2019. URL: https://doi.org/10.1002/jimd.12135, doi:10.1002/jimd.12135. This article has 32 citations and is from a peer-reviewed journal.

  13. (knerr2019expandingthegenetic pages 7-8): Ina Knerr, Roberto Colombo, Jill Urquhart, Ana Morais, Begona Merinero, Alfonso Oyarzabal, Belén Pérez, Simon A. Jones, Rahat Perveen, Mary A. Preece, Yvonne Rogers, Eileen P. Treacy, Philip Mayne, Giuseppe Zampino, Sabrina MacKinnon, Evangeline Wassmer, Wyatt W. Yue, Ian Robinson, Pilar Rodríguez‐Pombo, Simon E. Olpin, and Siddharth Banka. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. Journal of Inherited Metabolic Disease, 42:809-817, Aug 2019. URL: https://doi.org/10.1002/jimd.12135, doi:10.1002/jimd.12135. This article has 32 citations and is from a peer-reviewed journal.

  14. (bo2024primaryrolesof pages 18-19): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.

  15. (bo2024primaryrolesof pages 11-13): Tomoki Bo and Junichi Fujii. Primary roles of branched chain amino acids (bcaas) and their metabolism in physiology and metabolic disorders. Molecules, 30:56, Dec 2024. URL: https://doi.org/10.3390/molecules30010056, doi:10.3390/molecules30010056. This article has 61 citations.

  16. (sperringer2017branchedchainaminoacids pages 4-6): Justin E. Sperringer, Adele Addington, and Susan M. Hutson. Branched-chain amino acids and brain metabolism. Neurochemical Research, 42:1697-1709, Apr 2017. URL: https://doi.org/10.1007/s11064-017-2261-5, doi:10.1007/s11064-017-2261-5. This article has 265 citations and is from a peer-reviewed journal.

  17. (conway2021emergingmoonlightingfunctions pages 17-19): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  18. (conway2021emergingmoonlightingfunctions pages 1-3): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  19. (conway2021emergingmoonlightingfunctions pages 55-56): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  20. (mei2026branchedchainaminoacids pages 3-5): Jie Mei, Fu-yuan Yang, and Quan Gong. Branched-chain amino acids and insulin resistance in type 2 diabetes: from metabolic dysregulation to therapeutic targets. Frontiers in Endocrinology, Feb 2026. URL: https://doi.org/10.3389/fendo.2025.1643231, doi:10.3389/fendo.2025.1643231. This article has 4 citations.

  21. (sperringer2017branchedchainaminoacids pages 2-4): Justin E. Sperringer, Adele Addington, and Susan M. Hutson. Branched-chain amino acids and brain metabolism. Neurochemical Research, 42:1697-1709, Apr 2017. URL: https://doi.org/10.1007/s11064-017-2261-5, doi:10.1007/s11064-017-2261-5. This article has 265 citations and is from a peer-reviewed journal.

  22. (conway2021emergingmoonlightingfunctions pages 15-17): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  23. (lei2020acetylationpromotesbcat2 pages 4-5): Ming-Zhu Lei, Xu-Xu Li, Ye Zhang, Jin-Tao Li, Fan Zhang, Yi-Ping Wang, Miao Yin, Jia Qu, and Qun-Ying Lei. Acetylation promotes bcat2 degradation to suppress bcaa catabolism and pancreatic cancer growth. Signal Transduction and Targeted Therapy, May 2020. URL: https://doi.org/10.1038/s41392-020-0168-0, doi:10.1038/s41392-020-0168-0. This article has 132 citations and is from a peer-reviewed journal.

  24. (lei2020acetylationpromotesbcat2 pages 2-4): Ming-Zhu Lei, Xu-Xu Li, Ye Zhang, Jin-Tao Li, Fan Zhang, Yi-Ping Wang, Miao Yin, Jia Qu, and Qun-Ying Lei. Acetylation promotes bcat2 degradation to suppress bcaa catabolism and pancreatic cancer growth. Signal Transduction and Targeted Therapy, May 2020. URL: https://doi.org/10.1038/s41392-020-0168-0, doi:10.1038/s41392-020-0168-0. This article has 132 citations and is from a peer-reviewed journal.

  25. (sperringer2017branchedchainaminoacids pages 1-2): Justin E. Sperringer, Adele Addington, and Susan M. Hutson. Branched-chain amino acids and brain metabolism. Neurochemical Research, 42:1697-1709, Apr 2017. URL: https://doi.org/10.1007/s11064-017-2261-5, doi:10.1007/s11064-017-2261-5. This article has 265 citations and is from a peer-reviewed journal.

  26. (conway2021emergingmoonlightingfunctions pages 5-7): Myra Elizabeth Conway. Emerging moonlighting functions of the branched-chain aminotransferase proteins. May 2021. URL: https://doi.org/10.1089/ars.2020.8118, doi:10.1089/ars.2020.8118. This article has 28 citations and is from a domain leading peer-reviewed journal.

  27. (lei2020acetylationpromotesbcat2 pages 1-2): Ming-Zhu Lei, Xu-Xu Li, Ye Zhang, Jin-Tao Li, Fan Zhang, Yi-Ping Wang, Miao Yin, Jia Qu, and Qun-Ying Lei. Acetylation promotes bcat2 degradation to suppress bcaa catabolism and pancreatic cancer growth. Signal Transduction and Targeted Therapy, May 2020. URL: https://doi.org/10.1038/s41392-020-0168-0, doi:10.1038/s41392-020-0168-0. This article has 132 citations and is from a peer-reviewed journal.

  28. (zhang2026branchedchainaminoacid pages 4-5): Weiran Zhang, Jie Shen, Xuanyin Ding, Hele Liu, Xu Wang, and Dan Feng. Branched-chain amino acid transaminases as promising targets in tumor therapy. Frontiers in Cell and Developmental Biology, Feb 2026. URL: https://doi.org/10.3389/fcell.2026.1712076, doi:10.3389/fcell.2026.1712076. This article has 1 citations.

  29. (knerr2019expandingthegenetic pages 1-2): Ina Knerr, Roberto Colombo, Jill Urquhart, Ana Morais, Begona Merinero, Alfonso Oyarzabal, Belén Pérez, Simon A. Jones, Rahat Perveen, Mary A. Preece, Yvonne Rogers, Eileen P. Treacy, Philip Mayne, Giuseppe Zampino, Sabrina MacKinnon, Evangeline Wassmer, Wyatt W. Yue, Ian Robinson, Pilar Rodríguez‐Pombo, Simon E. Olpin, and Siddharth Banka. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. Journal of Inherited Metabolic Disease, 42:809-817, Aug 2019. URL: https://doi.org/10.1002/jimd.12135, doi:10.1002/jimd.12135. This article has 32 citations and is from a peer-reviewed journal.

  30. (knerr2019expandingthegenetic pages 8-9): Ina Knerr, Roberto Colombo, Jill Urquhart, Ana Morais, Begona Merinero, Alfonso Oyarzabal, Belén Pérez, Simon A. Jones, Rahat Perveen, Mary A. Preece, Yvonne Rogers, Eileen P. Treacy, Philip Mayne, Giuseppe Zampino, Sabrina MacKinnon, Evangeline Wassmer, Wyatt W. Yue, Ian Robinson, Pilar Rodríguez‐Pombo, Simon E. Olpin, and Siddharth Banka. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. Journal of Inherited Metabolic Disease, 42:809-817, Aug 2019. URL: https://doi.org/10.1002/jimd.12135, doi:10.1002/jimd.12135. This article has 32 citations and is from a peer-reviewed journal.

  31. (knerr2019expandingthegenetic pages 4-5): Ina Knerr, Roberto Colombo, Jill Urquhart, Ana Morais, Begona Merinero, Alfonso Oyarzabal, Belén Pérez, Simon A. Jones, Rahat Perveen, Mary A. Preece, Yvonne Rogers, Eileen P. Treacy, Philip Mayne, Giuseppe Zampino, Sabrina MacKinnon, Evangeline Wassmer, Wyatt W. Yue, Ian Robinson, Pilar Rodríguez‐Pombo, Simon E. Olpin, and Siddharth Banka. Expanding the genetic and phenotypic spectrum of branched‐chain amino acid transferase 2 deficiency. Journal of Inherited Metabolic Disease, 42:809-817, Aug 2019. URL: https://doi.org/10.1002/jimd.12135, doi:10.1002/jimd.12135. This article has 32 citations and is from a peer-reviewed journal.

  32. (haydar2018branchedchainamino pages 2-4): Sara Haydar, C. Lautier, and F. Grigorescu. Branched chain amino acids at the edge between mendelian and complex disorders. Acta endocrinologica, 14 2:238-247, Apr 2018. URL: https://doi.org/10.4183/aeb.2018.238, doi:10.4183/aeb.2018.238. This article has 11 citations.

  33. (he2026bcaasandrelated pages 7-8): Binfan He, Lingxi Li, Ye Liu, Mengmeng Hao, Ling Zhang, and Rongzhang He. Bcaas and related metabolic enzymes: partners in crime driving tumor development. Frontiers in Cell and Developmental Biology, Feb 2026. URL: https://doi.org/10.3389/fcell.2026.1748587, doi:10.3389/fcell.2026.1748587. This article has 0 citations.

  34. (zhang2026branchedchainaminoacid pages 13-14): Weiran Zhang, Jie Shen, Xuanyin Ding, Hele Liu, Xu Wang, and Dan Feng. Branched-chain amino acid transaminases as promising targets in tumor therapy. Frontiers in Cell and Developmental Biology, Feb 2026. URL: https://doi.org/10.3389/fcell.2026.1712076, doi:10.3389/fcell.2026.1712076. This article has 1 citations.

  35. (zhang2026branchedchainaminoacid pages 15-17): Weiran Zhang, Jie Shen, Xuanyin Ding, Hele Liu, Xu Wang, and Dan Feng. Branched-chain amino acid transaminases as promising targets in tumor therapy. Frontiers in Cell and Developmental Biology, Feb 2026. URL: https://doi.org/10.3389/fcell.2026.1712076, doi:10.3389/fcell.2026.1712076. This article has 1 citations.

  36. (zhang2026branchedchainaminoacid pages 11-13): Weiran Zhang, Jie Shen, Xuanyin Ding, Hele Liu, Xu Wang, and Dan Feng. Branched-chain amino acid transaminases as promising targets in tumor therapy. Frontiers in Cell and Developmental Biology, Feb 2026. URL: https://doi.org/10.3389/fcell.2026.1712076, doi:10.3389/fcell.2026.1712076. This article has 1 citations.

  37. (mei2026branchedchainaminoacids pages 5-6): Jie Mei, Fu-yuan Yang, and Quan Gong. Branched-chain amino acids and insulin resistance in type 2 diabetes: from metabolic dysregulation to therapeutic targets. Frontiers in Endocrinology, Feb 2026. URL: https://doi.org/10.3389/fendo.2025.1643231, doi:10.3389/fendo.2025.1643231. This article has 4 citations.

  38. (mei2026branchedchainaminoacids pages 1-2): Jie Mei, Fu-yuan Yang, and Quan Gong. Branched-chain amino acids and insulin resistance in type 2 diabetes: from metabolic dysregulation to therapeutic targets. Frontiers in Endocrinology, Feb 2026. URL: https://doi.org/10.3389/fendo.2025.1643231, doi:10.3389/fendo.2025.1643231. This article has 4 citations.

  39. (mei2026branchedchainaminoacids pages 2-3): Jie Mei, Fu-yuan Yang, and Quan Gong. Branched-chain amino acids and insulin resistance in type 2 diabetes: from metabolic dysregulation to therapeutic targets. Frontiers in Endocrinology, Feb 2026. URL: https://doi.org/10.3389/fendo.2025.1643231, doi:10.3389/fendo.2025.1643231. This article has 4 citations.

  40. (mei2026branchedchainaminoacids pages 6-8): Jie Mei, Fu-yuan Yang, and Quan Gong. Branched-chain amino acids and insulin resistance in type 2 diabetes: from metabolic dysregulation to therapeutic targets. Frontiers in Endocrinology, Feb 2026. URL: https://doi.org/10.3389/fendo.2025.1643231, doi:10.3389/fendo.2025.1643231. This article has 4 citations.

Artifacts

Citations

  1. conway2021emergingmoonlightingfunctions pages 3-5
  2. conway2021emergingmoonlightingfunctions pages 9-11
  3. bo2024primaryrolesof pages 9-11
  4. conway2021emergingmoonlightingfunctions pages 47-51
  5. conway2021emergingmoonlightingfunctions pages 7-9
  6. conway2021emergingmoonlightingfunctions pages 11-13
  7. conway2021emergingmoonlightingfunctions pages 55-56
  8. conway2021emergingmoonlightingfunctions pages 15-17
  9. bo2024primaryrolesof pages 11-13
  10. sperringer2017branchedchainaminoacids pages 1-2
  11. zhang2026branchedchainaminoacid pages 4-5
  12. knerr2019expandingthegenetic pages 8-9
  13. knerr2019expandingthegenetic pages 4-5
  14. wang2021branchedchainaminoacid pages 1-2
  15. zhang2026branchedchainaminoacid pages 13-14
  16. zhang2026branchedchainaminoacid pages 11-13
  17. mei2026branchedchainaminoacids pages 6-8
  18. conway2021emergingmoonlightingfunctions pages 13-15
  19. sperringer2017branchedchainaminoacids pages 6-7
  20. knerr2019expandingthegenetic pages 2-4
  21. knerr2019expandingthegenetic pages 5-7
  22. knerr2019expandingthegenetic pages 7-8
  23. bo2024primaryrolesof pages 18-19
  24. sperringer2017branchedchainaminoacids pages 4-6
  25. conway2021emergingmoonlightingfunctions pages 17-19
  26. conway2021emergingmoonlightingfunctions pages 1-3
  27. mei2026branchedchainaminoacids pages 3-5
  28. sperringer2017branchedchainaminoacids pages 2-4
  29. conway2021emergingmoonlightingfunctions pages 5-7
  30. knerr2019expandingthegenetic pages 1-2
  31. haydar2018branchedchainamino pages 2-4
  32. he2026bcaasandrelated pages 7-8
  33. zhang2026branchedchainaminoacid pages 15-17
  34. mei2026branchedchainaminoacids pages 5-6
  35. mei2026branchedchainaminoacids pages 1-2
  36. mei2026branchedchainaminoacids pages 2-3
  37. https://doi.org/10.3390/molecules30010056,
  38. https://doi.org/10.1089/ars.2020.8118,
  39. https://doi.org/10.1007/s11064-017-2261-5,
  40. https://doi.org/10.1002/jimd.12135,
  41. https://doi.org/10.1038/s41418-020-00644-4,
  42. https://doi.org/10.1038/s41392-020-0168-0,
  43. https://doi.org/10.3389/fendo.2025.1643231,
  44. https://doi.org/10.3389/fcell.2026.1712076,
  45. https://doi.org/10.4183/aeb.2018.238,
  46. https://doi.org/10.3389/fcell.2026.1748587,

📚 Additional Documentation

Notes

(BCAT2-notes.md)

BCAT2 (human) — curation notes

UniProtKB: O15382 | HGNC:977 | EC 2.6.1.42 | 392 aa (precursor; transit 1–27, chain 28–392)

Core biology (verified)

BCAT2 is the mitochondrial branched-chain-amino-acid aminotransferase (BCAT(m)), a
class-IV PLP-dependent aminotransferase. It catalyses the first, reversible step of BCAA
catabolism
: transamination of leucine, isoleucine and valine with 2-oxoglutarate
(α-ketoglutarate) to the corresponding branched-chain 2-oxo (keto) acid + L-glutamate. The
branched-chain α-ketoacids are then handed to the mitochondrial BCKDH complex.

Reactions (UniProt CATALYTIC ACTIVITY, ECO:0000269|PubMed:8702755):
- L-leucine + 2-oxoglutarate = 4-methyl-2-oxopentanoate (KIC) + L-glutamate [RHEA:18321]
- L-isoleucine + 2-oxoglutarate = (S)-3-methyl-2-oxopentanoate + L-glutamate [RHEA:24801]
- L-valine + 2-oxoglutarate = 3-methyl-2-oxobutanoate + L-glutamate [RHEA:24813]

Cofactor: pyridoxal 5'-phosphate (PLP), Schiff base to Lys-229 (MOD_RES
N6-(pyridoxal phosphate)lysine; ECO:0000269|PubMed:16141215, PubMed:17050531).
Quaternary structure: homodimer (PubMed:11264579). Has a redox-active CXXC center
(Cys-342/Cys-345); C342A reduces activity ~6-fold (PubMed:17050531). Many X-ray structures.

Localization: mitochondrion / mitochondrial matrix. TRANSIT peptide 1–27. Ubiquitous tissue
expression (PubMed:11170829); HPA tissue-enhanced in choroid. BCAT1 (chr 12) is the cytosolic
paralog; BCAT2 is on chr 19 (PubMed:9165094 proposed the BCAT1/BCAT2 nomenclature).

Disease

Autosomal-recessive Hypervalinemia and hyperleucine-isoleucinemia (HVLI; MIM:618850)
elevated plasma valine and leucine/isoleucine, headache, mild memory impairment. Caused by
loss-of-function BCAT2 variants (R170Q, E264K reduce catalytic activity; PubMed:25653144;
further variants V182G, 200-392del, A341T in PubMed:31177572). Vitamin B6 (PLP precursor)
supplementation lowered BCAA and improved brain lesions in a patient. This is the upstream
BCAA-elevation disorder; classic MSUD is the downstream BCKDH defect (ketoacid accumulation).
Dismech MSUD KB notes BCAT2 mediates BCAA transamination in skeletal muscle producing KIC
(~/repos/dismech/.../Maple_Syrup_Urine_Disease.yaml lines 749–752).

By-similarity / peripheral functions

UniProt FUNCTION notes (By similarity, from mouse O35855/O35854): BCAA catabolism supplies
lipogenic acetyl-CoA in adipocytes; acetyl-CoA is used by EP300 to acetylate/inhibit PRDM16,
preventing adipose browning; may transport branched-chain α-keto acids. These underlie the
ISS brown-fat annotations transferred from mouse.

Annotation-decision rationale

  • MF transaminase terms (GO:0004084 branched-chain; GO:0052654/5/6 leu/val/ile-specific):
    core. IDA (PMID:8702755), IBA, IEA(Rhea), TAS(PMID:9165094) all converge. ACCEPT.
  • BCAA catabolic BPs (GO:0009083, GO:0006550 ile, GO:0006574 val, GO:0006552 leu): core.
    ACCEPT. GO:0009081 (BCAA metabolic process) is a correct but general parent — KEEP_AS_NON_CORE.
  • GO:0009082 branched-chain amino acid BIOSYNTHETIC process (IEA-ARBA + TAS-PMID:8702755):
    the reaction is reversible, but in humans BCAAs are ESSENTIAL (not synthesised de novo);
    the physiological direction is catabolic. Biosynthesis is a bacterial/plant/fungal role of
    BCAT (ilvE). MARK_AS_OVER_ANNOTATED (not core; direction not physiological in human).
  • Localization GO:0005739 mitochondrion (IBA/IEA/IDA/ISS/HTP/TAS) and GO:0005759
    mitochondrial matrix (IEA/TAS): ACCEPT; matrix is the specific location.
  • GO:0003824 catalytic activity (IEA InterPro): correct but uninformative parent of the
    transaminase MF. MARK_AS_OVER_ANNOTATED.
  • protein binding GO:0005515 (4× IPI, interactome/BioID screens PMIDs 28514442, 29568061,
    33961781, 40205054; interactors HSPD1/P10809, HSPB1/P58557... note IntAct lists HSPD1 P10809
    and YBEY P58557): bare "protein binding" from high-throughput screens — MARK_AS_OVER_ANNOTATED
    per policy (do not REMOVE experimental IPIs).
  • Brown-fat ISS GO:0050873 (acts_upstream_of_negative_effect) and GO:1903444 (negative
    regulation of brown fat cell differentiation): transferred from mouse (O35855). Real but
    indirect/downstream metabolic-signalling role, not the core enzymatic function.
    KEEP_AS_NON_CORE.
  • GO:0097009 energy homeostasis (IEA Ensembl from mouse): broad downstream physiology;
    KEEP_AS_NON_CORE.

Cached key pubs 8702755 and 9165094 are ABSTRACT-ONLY (full_text_available: false); UniProt
cites their full text for the experimental catalytic/function annotations — defer to curator,
ACCEPT (do not REMOVE).

📄 View Raw YAML

id: O15382
gene_symbol: BCAT2
product_type: PROTEIN
status: INITIALIZED
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: >-
  BCAT2 (BCAT(m)) is the mitochondrial branched-chain-amino-acid aminotransferase, a
  class-IV pyridoxal 5'-phosphate (PLP)-dependent enzyme (EC 2.6.1.42) that catalyzes the
  first, reversible step of branched-chain amino acid (BCAA) catabolism. It transaminates
  L-leucine, L-isoleucine and L-valine with 2-oxoglutarate (alpha-ketoglutarate) to yield
  the corresponding branched-chain 2-oxo (keto) acids (4-methyl-2-oxopentanoate/KIC,
  (S)-3-methyl-2-oxopentanoate/KMV and 3-methyl-2-oxobutanoate/KIV) plus L-glutamate. The
  branched-chain keto acids are then passed to the mitochondrial branched-chain ketoacid
  dehydrogenase (BCKDH) complex for irreversible oxidative decarboxylation. The enzyme
  functions as a PLP-bound homodimer in the mitochondrial matrix, with the PLP cofactor
  forming a Schiff base (internal aldimine) to an active-site lysine (Lys-229), and carries
  a redox-active CXXC center (Cys-342/Cys-345) near the active site that couples catalysis
  to thiol redox state. BCAT2 is broadly expressed with highest activity in extrahepatic
  tissues such as skeletal muscle; the paralog BCAT1 is the cytosolic isozyme. Because
  BCAAs are essential amino acids in humans, the physiological direction of the reaction is
  catabolic (nitrogen removal), and loss of BCAT2 function causes an autosomal-recessive
  inborn error of metabolism (hypervalinemia and hyperleucine-isoleucinemia) with elevated
  plasma BCAAs.
alternative_products:
- name: A
  id: O15382-1
- name: B
  id: O15382-2
  sequence_note: VSP_000236
existing_annotations:
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: is_active_in
  review:
    summary: >-
      Phylogenetic (PAN-GO) inference that BCAT2 is active in the mitochondrion. Consistent
      with the cleaved N-terminal mitochondrial transit peptide (residues 1-27) and with all
      experimental localization evidence.
    action: ACCEPT
    reason: >-
      BCAT2 has a 27-residue mitochondrial targeting presequence and is well established as a
      mitochondrial-matrix enzyme; the IBA is correct. Mitochondrial matrix (GO:0005759) is
      the more specific location captured elsewhere in the annotation set.
    supported_by:
    - reference_id: PMID:9165094
      supporting_text: >-
        encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
- term:
    id: GO:0006550
    label: L-isoleucine catabolic process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: >-
      Phylogenetic inference that BCAT2 is involved in L-isoleucine catabolism. BCAT2
      transaminates isoleucine as the committed first step of its catabolism.
    action: ACCEPT
    reason: >-
      Isoleucine transamination is a core BCAT2 activity (GO:0052656), and the enzyme
      initiates isoleucine catabolism. Direct process annotation is appropriate and core.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0006574
    label: L-valine catabolic process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: involved_in
  review:
    summary: >-
      Phylogenetic inference that BCAT2 is involved in L-valine catabolism, initiating valine
      breakdown by transamination to 3-methyl-2-oxobutanoate.
    action: ACCEPT
    reason: >-
      Valine transamination (GO:0052655) is a core BCAT2 activity; the enzyme initiates valine
      catabolism. Valine is the most conspicuously elevated BCAA in BCAT2 deficiency, underscoring
      its physiological role here.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0052654
    label: L-leucine:2-oxoglutarate transaminase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: enables
  review:
    summary: >-
      Phylogenetic inference of L-leucine:2-oxoglutarate transaminase activity, one of the three
      substrate-specific BCAT activities. Corroborated by IDA (PMID:8702755) and Rhea IEA.
    action: ACCEPT
    reason: >-
      This substrate-specific molecular function is directly demonstrated for BCAT2 and is one
      of its core enzymatic activities.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
- term:
    id: GO:0052655
    label: L-valine:2-oxoglutarate transaminase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: enables
  review:
    summary: >-
      Phylogenetic inference of L-valine:2-oxoglutarate transaminase activity. Corroborated by IDA
      (PMID:8702755) and Rhea IEA (RHEA:24813).
    action: ACCEPT
    reason: >-
      Core substrate-specific transaminase activity of BCAT2, directly measured with valine as
      substrate.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0052656
    label: L-isoleucine:2-oxoglutarate transaminase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  qualifier: enables
  review:
    summary: >-
      Phylogenetic inference of L-isoleucine:2-oxoglutarate transaminase activity. Corroborated by
      IDA (PMID:8702755) and Rhea IEA (RHEA:24801).
    action: ACCEPT
    reason: >-
      Core substrate-specific transaminase activity of BCAT2, directly measured with isoleucine as
      substrate.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0003824
    label: catalytic activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  qualifier: enables
  review:
    summary: >-
      InterPro2GO mapping to the root catalytic-activity term. Correct but uninformative: BCAT2 is
      a specific PLP-dependent transaminase.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      GO:0003824 is a very general parent of the specific branched-chain aminotransferase activity
      (GO:0004084) and substrate-specific transaminase terms already annotated. It conveys no
      information beyond "is an enzyme" and is subsumed by the more precise MF annotations.
- term:
    id: GO:0004084
    label: branched-chain-amino-acid:2-oxoglutarate transaminase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  qualifier: enables
  review:
    summary: >-
      Combined multi-method IEA (ARBA + orthology + InterPro + EC:2.6.1.42) assigning the general
      branched-chain aminotransferase molecular function. This is the correct core EC-level activity.
    action: ACCEPT
    reason: >-
      GO:0004084 is the primary molecular function of BCAT2 (EC 2.6.1.42) and is independently
      supported by direct experimental evidence (IDA PMID:8702755) and TAS (PMID:9165094).
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  qualifier: located_in
  review:
    summary: >-
      IEA localization to mitochondrion (orthology to mouse O35855 plus UniProt SubCell SL-0173).
      Consistent with all other localization evidence.
    action: ACCEPT
    reason: >-
      Mitochondrial localization is firmly established; matrix is the specific compartment.
    supported_by:
    - reference_id: PMID:9165094
      supporting_text: >-
        encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
- term:
    id: GO:0009081
    label: branched-chain amino acid metabolic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000002
  qualifier: involved_in
  review:
    summary: >-
      InterPro2GO mapping to the general BCAA metabolic process. Correct but a broad parent of the
      specific catabolic-process annotations.
    action: KEEP_AS_NON_CORE
    reason: >-
      GO:0009081 (BCAA metabolic process) is a correct but general parent of the more specific and
      physiologically directional BCAA catabolic process (GO:0009083) and the amino-acid-specific
      catabolic terms already annotated. Keep as non-core; the catabolic terms carry the core signal.
- term:
    id: GO:0009082
    label: branched-chain amino acid biosynthetic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  qualifier: involved_in
  review:
    summary: >-
      ARBA machine-learning IEA (and an older TAS) annotating branched-chain amino acid BIOSYNTHETIC
      process. The BCAT reaction is chemically reversible, but in humans BCAAs are essential and are
      not synthesized de novo; the physiological direction is catabolic.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      The reversible transamination can in principle re-aminate branched-chain keto acids, but net
      de novo BCAA biosynthesis is a bacterial/plant/fungal role of BCAT-family enzymes (e.g. IlvE),
      not the human physiological function. The biosynthetic-process annotation is transferred from
      the family/EC and over-states the in vivo role; the catabolic annotations are correct and core.
      (Retained as an over-annotation rather than removed, since the underlying reversible chemistry
      is real.)
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0009083
    label: branched-chain amino acid catabolic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000117
  qualifier: involved_in
  review:
    summary: >-
      ARBA IEA to branched-chain amino acid catabolic process. This is the correct core biological
      process for BCAT2 and is independently supported by direct experimental evidence (IDA on the
      same term, PMID:8702755).
    action: ACCEPT
    reason: >-
      BCAT2 catalyzes the committed first step of BCAA catabolism; this is its central physiological
      role.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
    - reference_id: file:human/BCAT2/BCAT2-deep-research-falcon.md
      supporting_text: >-
        BCAT2 catalyzes the first step in mitochondrial BCAA catabolism
- term:
    id: GO:0052654
    label: L-leucine:2-oxoglutarate transaminase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000116
  qualifier: enables
  review:
    summary: >-
      Rhea-based IEA (RHEA:18321) for L-leucine:2-oxoglutarate transaminase activity. Matches the
      UniProt CATALYTIC ACTIVITY reaction for leucine.
    action: ACCEPT
    reason: >-
      Directly corresponds to a UniProt-documented catalytic reaction of BCAT2 and duplicates the
      experimentally supported (IDA/IBA) substrate-specific MF; correct and core.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
- term:
    id: GO:0052655
    label: L-valine:2-oxoglutarate transaminase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000116
  qualifier: enables
  review:
    summary: >-
      Rhea-based IEA (RHEA:24813) for L-valine:2-oxoglutarate transaminase activity, matching the
      UniProt CATALYTIC ACTIVITY reaction for valine.
    action: ACCEPT
    reason: >-
      Directly corresponds to a UniProt-documented catalytic reaction of BCAT2; core substrate-specific
      activity.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0052656
    label: L-isoleucine:2-oxoglutarate transaminase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000116
  qualifier: enables
  review:
    summary: >-
      Rhea-based IEA (RHEA:24801) for L-isoleucine:2-oxoglutarate transaminase activity, matching the
      UniProt CATALYTIC ACTIVITY reaction for isoleucine.
    action: ACCEPT
    reason: >-
      Directly corresponds to a UniProt-documented catalytic reaction of BCAT2; core substrate-specific
      activity.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:28514442
  qualifier: enables
  review:
    summary: >-
      Interaction detected in the BioPlex 2.0 high-throughput AP-MS interactome screen (interactors
      include HSPD1/P10809 and YBEY/P58557). "Protein binding" is uninformative about BCAT2's molecular
      function.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      GO:0005515 "protein binding" from a proteome-scale AP-MS screen conveys no specific functional
      information and is discouraged for core-function purposes. Per curation policy the experimental
      IPI is retained rather than removed, but it is marked as an over-annotation. (The
      BCAT2-HSPD1/HSP60 co-purification plausibly reflects mitochondrial chaperone association rather
      than a discrete functional partnership.)
    supported_by:
    - reference_id: PMID:28514442
      supporting_text: >-
        robust affinity purification-mass spectrometry methodology to elucidate protein
        interaction networks and co-complexes
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:29568061
  qualifier: enables
  review:
    summary: >-
      Interaction (with HSPD1/P10809) detected using the MAC-tag AP-MS/BioID proximity-labeling
      platform. Bare "protein binding" from a high-throughput mapping method.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      High-throughput proximity/AP-MS "protein binding" is uninformative for BCAT2 core function.
      Retained as an experimental IPI per policy but marked as over-annotation; the HSPD1/HSP60
      association is consistent with the mitochondrial matrix chaperone environment rather than a
      specific functional interaction.
    supported_by:
    - reference_id: PMID:29568061
      supporting_text: >-
        comprehensive mapping of protein interactions and subcellular localizations
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:33961781
  qualifier: enables
  review:
    summary: >-
      Interactions (HSPD1/P10809, YBEY/P58557) from the BioPlex 3.0 dual proteome-scale AP-MS
      interactome. Bare "protein binding" from a high-throughput screen.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      Proteome-scale AP-MS "protein binding" is uninformative about BCAT2's molecular function.
      Retained as an experimental IPI per policy, marked as over-annotation.
    supported_by:
    - reference_id: PMID:33961781
      supporting_text: >-
        cell-specific remodeling of the human interactome
- term:
    id: GO:0005515
    label: protein binding
  evidence_type: IPI
  original_reference_id: PMID:40205054
  qualifier: enables
  review:
    summary: >-
      Interactions (HSPD1/P10809, YBEY/P58557) from a multimodal cell-map interactome dataset. Bare
      "protein binding" from a high-throughput mapping study.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      High-throughput interactome "protein binding" is uninformative for BCAT2 core function.
      Retained as an experimental IPI per policy, marked as over-annotation.
    supported_by:
    - reference_id: PMID:40205054
      supporting_text: >-
        Multimodal cell maps as a foundation for structural and functional genomics
- term:
    id: GO:0005759
    label: mitochondrial matrix
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: is_active_in
  review:
    summary: >-
      Ensembl-Compara orthology IEA (from mouse) placing BCAT2 activity in the mitochondrial matrix,
      the specific compartment where BCAA transamination occurs.
    action: ACCEPT
    reason: >-
      Mitochondrial matrix is the correct, specific subcellular location for this soluble matrix
      enzyme, consistent with its cleaved transit peptide and TAS/Reactome annotations.
    supported_by:
    - reference_id: PMID:9165094
      supporting_text: >-
        encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
- term:
    id: GO:0006552
    label: L-leucine catabolic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: >-
      Ensembl-Compara orthology IEA (from mouse) for L-leucine catabolic process. BCAT2 initiates
      leucine catabolism by transamination to 4-methyl-2-oxopentanoate (KIC).
    action: ACCEPT
    reason: >-
      Leucine transamination (GO:0052654) is a core BCAT2 activity and the enzyme initiates leucine
      catabolism; the process annotation is appropriate and core.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0006574
    label: L-valine catabolic process
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: >-
      Ensembl-Compara orthology IEA (from mouse) for L-valine catabolic process. Duplicates the IBA
      valine-catabolism annotation; correct and core.
    action: ACCEPT
    reason: >-
      BCAT2 initiates valine catabolism; core biological process.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0097009
    label: energy homeostasis
  evidence_type: IEA
  original_reference_id: GO_REF:0000107
  qualifier: involved_in
  review:
    summary: >-
      Ensembl-Compara orthology IEA (from mouse) for energy homeostasis. BCAA catabolism feeds
      acetyl-CoA/succinyl-CoA into the TCA cycle and BCAT2 loss alters energy expenditure in mice,
      but this is a broad downstream physiological consequence rather than the enzyme's molecular role.
    action: KEEP_AS_NON_CORE
    reason: >-
      Energy homeostasis is a general, pleiotropic downstream process to which BCAA catabolism
      contributes indirectly (e.g. BCAT2-knockout mice show increased energy expenditure). It is not
      the core enzymatic function; keep as non-core.
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  qualifier: located_in
  review:
    summary: >-
      Direct immunofluorescence localization (Human Protein Atlas) placing BCAT2 in the mitochondrion.
    action: ACCEPT
    reason: >-
      Experimental (IDA) immunofluorescence confirms mitochondrial localization, in agreement with
      all other evidence; matrix is the specific compartment.
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  qualifier: located_in
  review:
    summary: >-
      Sequence-similarity localization to mitochondrion, transferred from rat ortholog (O35854).
      Consistent with the transit peptide and experimental data.
    action: ACCEPT
    reason: >-
      Mitochondrial localization is firmly established across evidence types.
    supported_by:
    - reference_id: PMID:9165094
      supporting_text: >-
        encode mature proteins of 41.2 and 41.3 kDa with presequences of 27 amino acids
- term:
    id: GO:0009083
    label: branched-chain amino acid catabolic process
  evidence_type: IDA
  original_reference_id: PMID:8702755
  qualifier: involved_in
  review:
    summary: >-
      Direct experimental evidence that BCAT2 participates in BCAA catabolism: BCAT activity toward
      leucine, isoleucine and valine was measured, and the human/yeast homologs encode the
      branched-chain aminotransferases initiating BCAA breakdown.
    action: ACCEPT
    reason: >-
      This is the core biological process of BCAT2, supported by direct enzymatic assays with all
      three BCAA substrates.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0050873
    label: brown fat cell differentiation
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  qualifier: acts_upstream_of_negative_effect
  review:
    summary: >-
      Sequence-similarity annotation transferred from mouse (O35855): BCAA catabolism supplies
      lipogenic acetyl-CoA that EP300/p300 uses to acetylate and inhibit PRDM16, preventing adipose
      browning. A real but indirect metabolic-signalling role, downstream of the catabolic function.
    action: KEEP_AS_NON_CORE
    reason: >-
      This links BCAT2 to a specific downstream developmental/metabolic output (brown fat
      differentiation) via acetyl-CoA supply and PRDM16 regulation. It is genuine (documented in
      mouse orthologs) but is a peripheral, indirect role rather than BCAT2's core enzymatic function;
      keep as non-core.
    supported_by:
    - reference_id: UniProtKB:O35855
      supporting_text: >-
        acetyl-CoA derived from branched chain amino acid catabolism is used by EP300/p300 to
        acetylate and inhibit PRDM16, thereby preventing adipose tissue browning
    additional_reference_ids:
    - UniProtKB:O35855
- term:
    id: GO:0004084
    label: branched-chain-amino-acid:2-oxoglutarate transaminase activity
  evidence_type: IDA
  original_reference_id: PMID:8702755
  qualifier: enables
  review:
    summary: >-
      Direct experimental demonstration of branched-chain aminotransferase activity for the cloned
      mitochondrial enzyme, assayed with leucine, isoleucine and valine as substrates.
    action: ACCEPT
    reason: >-
      This is the core molecular function of BCAT2 (EC 2.6.1.42), established by direct enzymatic
      assay.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:1903444
    label: negative regulation of brown fat cell differentiation
  evidence_type: ISS
  original_reference_id: GO_REF:0000024
  qualifier: involved_in
  review:
    summary: >-
      Sequence-similarity annotation transferred from mouse (MGI:1276534) for negative regulation of
      brown fat cell differentiation, via BCAA-catabolism-derived acetyl-CoA and EP300/PRDM16
      signalling.
    action: KEEP_AS_NON_CORE
    reason: >-
      Same indirect brown-fat/PRDM16 axis as GO:0050873; a genuine downstream metabolic-signalling
      role documented in mouse but peripheral to BCAT2's core transaminase function. Keep as non-core.
    supported_by:
    - reference_id: UniProtKB:O35855
      supporting_text: >-
        acetyl-CoA derived from branched chain amino acid catabolism is used by EP300/p300 to
        acetylate and inhibit PRDM16, thereby preventing adipose tissue browning
    additional_reference_ids:
    - UniProtKB:O35855
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: HTP
  original_reference_id: PMID:34800366
  qualifier: located_in
  review:
    summary: >-
      High-throughput proteomic assignment of BCAT2 to the high-confidence human mitochondrial
      proteome (MitoCoP).
    action: ACCEPT
    reason: >-
      Corroborates mitochondrial localization by an orthogonal high-throughput proteomics method,
      consistent with all other evidence.
    supported_by:
    - reference_id: PMID:34800366
      supporting_text: >-
        defined a mitochondrial high-confidence proteome of >1,100 proteins (MitoCoP)
- term:
    id: GO:0052654
    label: L-leucine:2-oxoglutarate transaminase activity
  evidence_type: IDA
  original_reference_id: PMID:8702755
  qualifier: enables
  review:
    summary: >-
      Direct experimental demonstration of L-leucine transaminase activity for the mitochondrial
      branched-chain aminotransferase.
    action: ACCEPT
    reason: >-
      Core substrate-specific molecular function, directly measured with leucine as substrate.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0052655
    label: L-valine:2-oxoglutarate transaminase activity
  evidence_type: IDA
  original_reference_id: PMID:8702755
  qualifier: enables
  review:
    summary: >-
      Direct experimental demonstration of L-valine transaminase activity for the mitochondrial
      branched-chain aminotransferase.
    action: ACCEPT
    reason: >-
      Core substrate-specific molecular function, directly measured with valine as substrate.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0052656
    label: L-isoleucine:2-oxoglutarate transaminase activity
  evidence_type: IDA
  original_reference_id: PMID:8702755
  qualifier: enables
  review:
    summary: >-
      Direct experimental demonstration of L-isoleucine transaminase activity for the mitochondrial
      branched-chain aminotransferase.
    action: ACCEPT
    reason: >-
      Core substrate-specific molecular function, directly measured with isoleucine as substrate.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        Activity of branched-chain amino acid aminotransferase was measured in the wild-type
        and mutants with either leucine, isoleucine, or valine as substrates
- term:
    id: GO:0005759
    label: mitochondrial matrix
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-508179
  qualifier: located_in
  review:
    summary: >-
      Reactome traceable-author-statement placing the BCAT2 reaction in the mitochondrial matrix
      (reverse direction: keto acids + glutamate to BCAAs + alpha-ketoglutarate).
    action: ACCEPT
    reason: >-
      Mitochondrial matrix is the correct specific location for this enzyme; Reactome annotation is
      consistent with all other evidence.
- term:
    id: GO:0005759
    label: mitochondrial matrix
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-70724
  qualifier: located_in
  review:
    summary: >-
      Reactome traceable-author-statement placing the BCAT2 reaction in the mitochondrial matrix
      (forward catabolic direction: BCAAs + alpha-ketoglutarate to keto acids + glutamate).
    action: ACCEPT
    reason: >-
      Mitochondrial matrix is the correct specific location for this enzyme; consistent with all
      other evidence.
- term:
    id: GO:0004084
    label: branched-chain-amino-acid:2-oxoglutarate transaminase activity
  evidence_type: TAS
  original_reference_id: PMID:9165094
  qualifier: enables
  review:
    summary: >-
      Traceable author statement (cloning of rat and human BCATm) supporting the branched-chain
      aminotransferase molecular function. This paper established the BCAT1/BCAT2 nomenclature and
      showed the cloned enzyme has BCAT activity.
    action: ACCEPT
    reason: >-
      Corroborates the core EC-level molecular function of BCAT2 with TAS from the defining cloning
      paper.
    supported_by:
    - reference_id: PMID:9165094
      supporting_text: >-
        the protein exhibits BCAT activity and correct processing of the mitochondrial targeting
        sequence
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: TAS
  original_reference_id: PMID:9165094
  qualifier: located_in
  review:
    summary: >-
      Traceable author statement for mitochondrial localization from the BCATm cloning paper, which
      demonstrated correct processing of the mitochondrial targeting presequence.
    action: ACCEPT
    reason: >-
      Mitochondrial localization is established; the cloning paper showed proper mitochondrial
      targeting-sequence processing.
    supported_by:
    - reference_id: PMID:9165094
      supporting_text: >-
        the protein exhibits BCAT activity and correct processing of the mitochondrial targeting
        sequence
- term:
    id: GO:0009082
    label: branched-chain amino acid biosynthetic process
  evidence_type: TAS
  original_reference_id: PMID:8702755
  qualifier: involved_in
  review:
    summary: >-
      Older TAS annotating branched-chain amino acid BIOSYNTHETIC process, presumably reflecting the
      chemically reversible transamination. In humans BCAAs are essential and not synthesized de novo,
      so the physiological direction is catabolic.
    action: MARK_AS_OVER_ANNOTATED
    reason: >-
      The reversible reaction can re-aminate branched-chain keto acids, but net BCAA biosynthesis is a
      microbial/plant role of BCAT-family enzymes, not the human function; humans require dietary BCAAs.
      The biosynthetic-process annotation over-states the in vivo role. Retained as an over-annotation
      (the reversible chemistry is real) rather than removed.
    supported_by:
    - reference_id: PMID:8702755
      supporting_text: >-
        code for cytosolic and mitochondrial branched-chain amino acid aminotransferases
- term:
    id: GO:0030170
    label: pyridoxal phosphate binding
  evidence_type: IDA
  original_reference_id: PMID:8702755
  qualifier: enables
  review:
    summary: >-
      Proposed annotation (not in current GOA): BCAT2 binds pyridoxal 5'-phosphate (PLP) as its
      essential catalytic cofactor. UniProt records PLP as the cofactor (COFACTOR, from crystallographic
      studies) and a Schiff-base MOD_RES at Lys-229; PLP binding is required for the demonstrated
      aminotransferase activity.
    action: NEW
    reason: >-
      PLP-binding is a well-established, structurally and biochemically documented molecular function of
      this class-IV PLP-dependent aminotransferase (many BCATm crystal structures resolve the PLP
      cofactor; the Schiff-base lysine is annotated in UniProt) and directly underlies its catalytic
      activity. It is currently missing from GOA and is added here as a core function.
    supported_by:
    - reference_id: file:human/BCAT2/BCAT2-uniprot.txt
      supporting_text: "Name=pyridoxal 5'-phosphate; Xref=ChEBI:CHEBI:597326;"
core_functions:
- description: >-
    BCAT2 is the mitochondrial branched-chain-amino-acid aminotransferase (EC 2.6.1.42) that
    catalyzes the first, reversible step of branched-chain amino acid catabolism: PLP-dependent
    transamination of L-leucine, L-isoleucine and L-valine with 2-oxoglutarate to give the
    corresponding branched-chain 2-oxo acids (KIC, KMV, KIV) plus L-glutamate, feeding the products
    to the mitochondrial BCKDH complex. It acts as a homodimer in the mitochondrial matrix.
  molecular_function:
    id: GO:0004084
    label: branched-chain-amino-acid:2-oxoglutarate transaminase activity
  directly_involved_in:
  - id: GO:0009083
    label: branched-chain amino acid catabolic process
  locations:
  - id: GO:0005759
    label: mitochondrial matrix
  substrates:
  - id: CHEBI:15603
    label: L-leucine
  - id: CHEBI:17191
    label: L-isoleucine
  - id: CHEBI:16414
    label: L-valine
  - id: CHEBI:16810
    label: 2-oxoglutarate
  supported_by:
  - reference_id: PMID:8702755
    supporting_text: >-
      Activity of branched-chain amino acid aminotransferase was measured in the wild-type
      and mutants with either leucine, isoleucine, or valine as substrates
  - reference_id: PMID:9165094
    supporting_text: >-
      the protein exhibits BCAT activity and correct processing of the mitochondrial targeting
      sequence
- description: >-
    Catalysis requires the cofactor pyridoxal 5'-phosphate (PLP), which is bound at the active site
    via a Schiff-base (internal aldimine) linkage to Lys-229 and cycles between the aldimine (PLP)
    and pyridoxamine (PMP) forms during the ping-pong transamination mechanism. PLP binding is
    essential for BCAT2 aminotransferase activity, and the disease-relevant loss of activity can be
    partially rescued by vitamin B6 (PLP precursor) supplementation.
  molecular_function:
    id: GO:0030170
    label: pyridoxal phosphate binding
  directly_involved_in:
  - id: GO:0009083
    label: branched-chain amino acid catabolic process
  locations:
  - id: GO:0005759
    label: mitochondrial matrix
proposed_new_terms: []
suggested_questions:
- question: >-
    In human tissues, does BCAT2 carry any physiologically relevant biosynthetic (re-amination)
    flux toward BCAAs, or is the net direction exclusively catabolic given the essentiality of
    dietary BCAAs?
- question: >-
    To what extent do the reported BCAT2 protein-protein interactions (e.g. with HSPD1/HSP60) and
    the CXXC-dependent metabolon with the BCKDH E1 subunit represent discrete functional partnerships
    versus co-purification within the mitochondrial matrix?
suggested_experiments:
- description: >-
    Quantify BCAA-to-BCKA flux directionality in situ (e.g. stable-isotope 15N/13C tracing) in
    BCAT2-expressing human muscle vs liver models to determine whether any net biosynthetic
    re-amination occurs physiologically.
- description: >-
    Reconstitute the BCAT2-BCKDH E1 metabolon in vitro with reduced vs oxidized CXXC-center BCAT2
    (and C342A/C345A mutants) to test how the redox state of the CXXC center gates substrate
    channeling and overall BCAA oxidation rate.
references:
- id: file:human/BCAT2/BCAT2-deep-research-falcon.md
  title: Deep research report on BCAT2 (falcon/Edison)
  findings: []
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: >-
      AI-generated deep-research synthesis (falcon/Edison). Used to corroborate the core BCAA
      catabolic pathway framing; primary catalytic/localization claims are independently grounded
      in UniProt O15382 and PMID:8702755/PMID:9165094.
- id: GO_REF:0000002
  title: Gene Ontology annotation through association of InterPro records with GO
    terms
  findings: []
- id: GO_REF:0000024
  title: Manual transfer of experimentally-verified manual GO annotation data to orthologs
    by curator judgment of sequence similarity
  findings: []
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
  findings: []
- id: GO_REF:0000052
  title: Gene Ontology annotation based on curation of immunofluorescence data
  findings: []
- id: GO_REF:0000107
  title: Automatic transfer of experimentally verified manual GO annotation data to
    orthologs using Ensembl Compara
  findings: []
- id: GO_REF:0000116
  title: Automatic Gene Ontology annotation based on Rhea mapping
  findings: []
- id: GO_REF:0000117
  title: Electronic Gene Ontology annotations created by ARBA machine learning models
  findings: []
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods
  findings: []
- id: PMID:28514442
  title: Architecture of the human interactome defines protein communities and disease
    networks.
  findings: []
  reference_review:
    relevance: LOW
    correctness: VERIFIED
    review_notes: >-
      BioPlex 2.0 proteome-scale AP-MS; source of a bare "protein binding" IPI (interactors incl.
      HSPD1/P10809). PMC full text confirmed. Not informative about BCAT2's catalytic function.
- id: PMID:29568061
  title: An AP-MS- and BioID-compatible MAC-tag enables comprehensive mapping of protein
    interactions and subcellular localizations.
  findings: []
  reference_review:
    relevance: LOW
    correctness: VERIFIED
    review_notes: >-
      MAC-tag AP-MS/BioID methods paper; source of a bare "protein binding" IPI. Uninformative about
      BCAT2 molecular function.
- id: PMID:33961781
  title: Dual proteome-scale networks reveal cell-specific remodeling of the human
    interactome.
  findings: []
  reference_review:
    relevance: LOW
    correctness: VERIFIED
    review_notes: >-
      BioPlex 3.0 interactome; source of bare "protein binding" IPIs. Uninformative about catalytic
      function.
- id: PMID:34800366
  title: Quantitative high-confidence human mitochondrial proteome and its dynamics
    in cellular context.
  findings: []
  reference_review:
    relevance: MEDIUM
    correctness: VERIFIED
    review_notes: >-
      MitoCoP high-confidence mitochondrial proteome; supports mitochondrial localization (HTP).
      PMC full text confirmed.
- id: PMID:40205054
  title: Multimodal cell maps as a foundation for structural and functional genomics.
  findings: []
  reference_review:
    relevance: LOW
    correctness: VERIFIED
    review_notes: >-
      Multimodal cell-map interactome; source of bare "protein binding" IPIs. Uninformative about
      catalytic function.
- id: PMID:8702755
  title: Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic
    and mitochondrial branched-chain amino acid aminotransferases.
  findings: []
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: >-
      Cached abstract-only (full_text_available: false); UniProt cites the full text (ECO:0000269)
      for the EC 2.6.1.42 catalytic activity and BCAA-catabolism FUNCTION. Directly establishes BCAT
      activity toward Leu/Ile/Val. Underlies the core MF and BP annotations.
- id: PMID:9165094
  title: Cloning of the rat and human mitochondrial branched chain aminotransferases
    (BCATm).
  findings: []
  reference_review:
    relevance: HIGH
    correctness: VERIFIED
    review_notes: >-
      Cached abstract-only; defining cloning paper that proposed BCAT1 (cytosolic)/BCAT2
      (mitochondrial) nomenclature, mapped BCAT2 to chromosome 19, and showed a 27-residue
      mitochondrial presequence and BCAT activity. Supports MF and mitochondrial localization.
- id: Reactome:R-HSA-508179
  title: "a-ketoisocaproate, a-keto-b-methylvalerate, or a-ketoisovalerate + glutamate"
  findings: []
- id: Reactome:R-HSA-70724
  title: "leu, ile, or val + alpha-ketoglutarate <=> a-ketoisocaproate, a-keto-b-methylvalerate,"
  findings: []
- id: UniProtKB:O35855
  title: Branched-chain-amino-acid aminotransferase, mitochondrial (Mus musculus)
  findings: []
  reference_review:
    relevance: MEDIUM
    correctness: VERIFIED
    review_notes: >-
      Mouse ortholog UniProt entry; source of the By-similarity FUNCTION statement (BCAA-catabolism
      acetyl-CoA used by EP300 to acetylate/inhibit PRDM16, preventing adipose browning) underlying
      the ISS brown-fat annotations. Verbatim supporting text quoted from the human O15382 UniProt
      FUNCTION comment, which attributes the statement to O35855.